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INTRODUCCIÓN 
La enfermerdad arterial periférica (EAP) en las etapas intermedias es responsable de la 
incapacidad para caminar y de la reducción de la calidad de vida entre el 3% y 10% de la 
población y entre el 15% y 20% de los pacientes mayores de 70 años. La cirugía no puede 
revertir completamente la incapacidad y presenta riesgo de complicaciones y altos costos. El 
ejercicio es una intervención efectiva, que puede aumentar la capacidad funcional de los 
pacientes con EAP y claudicación. Desafortunadamente, los programas recomendados 
realizados en un hospital bajo supervisión están poco desarrollados y limitados por una baja 
adherencia. Por lo tanto, en base a la evidencia científica, el enfoque del ejercicio en EAP 
está avanzando progresivamente hacia nuevos modelos de intervención y formas alternativas 
de ejercicio. Hace quince años, Manfredini F y colaboradores desarrollaron un modelo 
estructurado original de ejercicio sin supervisión en pacientes con EAP, basado en sesiones 
de caminata sin síntomas en el hogar a una velocidad prescrita con controles en el hospital. 
El modelo también fue probado con éxito en pacientes en diálisis y supervivientes de 
accidente cerebrovascular. 
La presente tesis, la cual se centra en el tratamiento de pacientes con EAP con claudicación, 
en particular en el tratamiento con ejercicios, tiene como objetivo probar la hipótesis de que 
los resultados de rehabilitación están asociados con mejores resultados clínicos y vasculares 
a largo plazo. Este problema, descrito en la literatura para la rehabilitación cardíaca, se 
describe pobremente en la rehabilitación vascular. La confirmación de la hipótesis subraya 
la importancia de los programas de rehabilitación que también son sostenibles en pacientes 
ancianos y frágiles, lo que puede tener un impacto positivo en el destino de los pacientes con 
EAP. 
OBJETIVOS 
Este estudio evalúa retrospectivamente la asociación de los resultados de rehabilitación 
después de un programa original estructurado en el hogar y el riesgo de revascularizaciones 
periféricas y la mortalidad en pacientes ancianos con EAP con claudicación. 
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SUJETOS Y MÉTODOS 
Ochocientos treinta y cinco pacientes se incluyeron en el estudio. Se midió el índice tobillo-
braquial (ABI) y la velocidad máxima de caminata (Smax) mediante una prueba incremental 
en cinta rodante, al inicio y alta de un programa de caminata sin síntomas prescrito en un 
hospital y ejecutado en casa. Para el análisis, los pacientes se dividieron según el valor ABI 
de referencia en el grupo Severo (ABI ≤0,5) o Moderado (ABI ≥0,5) y de acuerdo con los 
resultados de rehabilitación hemodinámicos o funcionales en los que se ajustaban (ABI ≥ 
0.10 y / o Smax ≥ 0.5 km / h) o no a la rehabilitación. Se recopilaron datos sobre las 
revascularizaciones y la mortalidad relacionadas con EAP durante un período de 3 años, 
según el registro regional de la región de Emilia-Romagna. 
RESULTADOS 
De acuerdo con los criterios de inclusión, los pacientes de <60 u 80 años, con un valor de 
ABI ≥0.80 o no medible, o los pacientes que interrumpieron el programa de rehabilitación 
fueron excluidos. La muestra final incluyó 457 pacientes, específicamente, 146 graves y 311 
moderados. 
La población total, con valores funcionales y hemodinámicos significativamente mejorados 
en el momento del alta, durante el período de seguimiento mostró 56 revascularizaciones y 
69 muertes, con una tasa de revascularización (12%) fuertemente asociada con el ABI al alta 
(HR: 0,03; CI 95%: 0,004-0,16). 
Los pacientes graves que en el momento del alta mostraron una adherencia, resultados 
funcionales y hemodinámicos superpuestos con aquellos moderados, en el período de 
seguimiento mostraron una esperada mayor tasa de revascularización (17% vs. 10%, 
respectivamente, p <0,001) y muerte (29% vs. 8%, respectivamente; p <0.001). Sin embargo, 
los pacientes del grupo severo con un ABI mejorado mostraron una tasa de revascularización 
más baja que aquellos con ABI grave que no respondían (13% vs. 21%, respectivamente; 
HR: 0.52; 0.201.40) y ninguna diferencia para el grupo Moderado (9%). Se observaron 
resultados superponibles para los que respondían a la Smax (13% vs. 21%; HR: 0,55; Grupo 
Moderado: 10%). Entre los que respondían se observaron beneficios similares para la 
mortalidad. 
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CONCLUSIONES 
Los pacientes ancianos con EAP grave, que al momento del alta hospitalaria lograron mejoras 
hemodinámicas y de movilidad aceptables, mostraron tasas más bajas de revascularización 
periférica y muerte a los 3 años de seguimiento, lo cual es comparable a los pacientes con 
enfermedad moderada. Los programas centrados en el paciente que son reproducibles a bajo 
costo en un entorno ambulatorio y capaces de mejorar tanto la función como la hemodinámica 
con bajas dosis de ejercicio, incluso en presencia de una enfermedad grave, pueden 
representar una opción en la toma de decisiones para pacientes ancianos con poca movilidad. 
A nuestro conocimiento, los resultados actuales representan un informe novedoso que 
requiere una evaluación adicional en estudios prospectivos. 
Palabras clave: Mortalidad; Ejercicio; Enfermedad de la Arteria Periférica; Rehabilitación; 
Procedimientos quirúrgicos vasculares. 
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INTRODUCTION 
Peripheral artery disease (PAD) at intermediate stages is responsible for walking disability 
and quality of life reduction among 3-10% of the population and 15-20% of patients over 70 
years. Surgery is unable to fully reverse the disability and has a risk of complications and 
high costs. Exercise is an effective intervention, which can increase the functional capacity 
of patients with PAD and claudication. Unfortunately, the recommended programs carried 
out at a hospital under supervision are poorly available and limited by low adherence. 
Therefore, based on new evidence, the approach to exercise in PAD is progressively moving 
towards novel models of intervention and alternative forms of exercise. Fifteen years ago, an 
original structured model of exercise without supervision, based on home-based symptom-
free walking sessions at a prescribed speed with check-ups at the hospital, was developed by 
Manfredini F and coworkers in PAD. The model was also successfully tested in dialysis 
patients and stroke survivors. 
The present thesis, which focuses on the management of PAD patients with claudication, in 
particular on the exercise therapy, aims to test the hypothesis that rehabilitative outcomes 
may be associated with better long-term vascular and clinical outcomes. This issue, reported 
in the literature for cardiac rehabilitation, is poorly described for vascular rehabilitation. 
Confirmation of the hypothesis would underline the importance of rehabilitative programs 
that are also sustainable in elderly and frail patients, which may have a positive impact on 
the fate of patients with PAD. 
AIMS/OBJECTIVES 
This study retrospectively evaluated the association between rehabilitative outcomes 
following an original structured home-based program and the risk of peripheral 
revascularizations and mortality in elderly PAD patients with claudication.  
SUBJECTS AND METHODS 
 Eight-hundred thirty-five patients were enrolled. Ankle-brachial index (ABI) and maximal 
walking speed (Smax) by an incremental treadmill test were measured at baseline and at 
discharge from a symptom-free walking program prescribed at a hospital and executed at 
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home. For the analysis, patients were divided according to a baseline ABI value into the 
Severe (ABI ≤0.5) or Moderate (ABI ≥0.5) group and according to hemodynamic or 
functional rehabilitative outcomes into responders (ABI ≥ 0.10 and/or Smax ≥ 0.5 km/h) or 
non-responders to rehabilitation. Data about PAD-related revascularizations and mortality 
for a 3-year period were collected for the regional registry of the Emilia-Romagna Region.  
RESULTS 
According to the inclusion criteria, patients aged <60 or >80 years, with ABI value ≥0.80 or 
unmeasurable, or patients who interrupted the rehabilitation program were excluded. The 
final sample included 457 patients, specifically, 146 Severe and 311 Moderate.  
 The whole population, with significantly improved functional and hemodynamic values at 
discharge, at follow-up showed 56 revascularizations and 69 deaths, with the rate of 
revascularization (12%) strongly associated with ABI at discharge (hazard ratio, HR:0.03; 
95% confidence interval 0.004−0.16).  
Severe patients who at discharge showed superimposable adherence, functional and 
hemodynamic outcomes compared to Moderate, at follow-up showed an expected higher rate 
of revascularization (17% vs 10%, respectively p<0.001) and death (29% vs 8%, 
respectively; p<0.001). However, Severe patients with an improved ABI showed a lower rate 
of revascularization than Severe ABI nonresponders (13% vs 21%, respectively; HR:0.52; 
0.20−1.40) and no difference from Moderate (9%). Superimposable outcomes were observed 
for Smax responders (13% vs. 21%; HR: 0.55; Moderate 10%). Among responders, similar 
benefits were observed for mortality.  
CONCLUSIONS 
Elderly patients with severe PAD, who at discharge from rehabilitation attained acceptable 
hemodynamic and mobility improvements, showed lower rates of peripheral 
revascularization and death at 3-year follow-up, which is comparable to patients with 
moderate disease. Patient-centered programs that are reproducible at low cost in an outpatient 
setting and able to improve both function and hemodynamics with low doses of exercise even 
in the presence of severe disease may represent an option in the decision-making for elderly 
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patients with low mobility. To the best of our knowledge, the present results represent a novel 
report that requires further assessment in prospective studies.   
Keywords: Mortality; Exercise; Peripheral Artery Disease; Rehabilitation; Vascular surgical 
procedures. 
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1. PERIPHERAL ARTERY DISEASE: THE BURDEN 
 
Peripheral artery disease (PAD) of the lower limbs is a chronic arterial occlusive disease 
secondary to alterations that cause irreversible damage to the wall of arteries of different 
caliber. The result is insufficient oxygen delivery in the distal districts to the alteration itself 
[1]. The disease is often underestimated, notwithstanding the reduction of function and of the 
quality of life (QoL) at an intermediate stage, and has a high prevalence [2,3]. 
More than 200 million people worldwide are living with PAD, with the number of people 
affected continuously rising especially in low- and middle-income countries [2,4]. In these 
countries, the increase in the prevalence of affected individuals over a 10-year period has 
more than doubled compared with high-income countries [1,4,5]. In general, the prevalence 
of PAD increases progressively with age, in particular after 40 years of age, even if it is 
progressively also involving young adults [1,3]. It ranges from 0.9% between the ages of 40 
and 49 to 14.5% after 70 years of age [6] and up to 57% among patients above 85 years of 
age [7] when evaluated on the basis of a low (< 0.90) ankle-brachial index (ABI) or the ratio 
of blood pressure in the lower legs to blood pressure in the arms in either leg [1] .  
In the United States, where the prevalence is estimated to be approximately 5.9% of 
Americans over 40 years of age, high-risk populations show a prevalence up to 30%, such as 
African Americans and Hispanics [6,8,9]. 
The prevalence of PAD tends to be twice as high in males than in women aged 50-70 years, 
with a tendency towards a balance after age 70 years [6-7, 10-12]. However, the burden of 
PAD is changing with prevalence, disability and mortality associated with PAD particularly 
increased in women in the last 20 years [1,13,14]. Few data on the incidence of PAD are 
available. Mean annual incidence rates of PAD and critical limb ischemia (CLI) were of 
2.35% and 0.35%, respectively, among nearly 12 million insured American adults [15]. 
PAD also indicates a walking disability. Worldwide, it is estimated that approximately 40 
million individuals experience disability related to the classic symptoms of intermittent 
claudication (IC) with a prevalence of approximately 10% in the population according to 
recent reports from general practitioners [9,16].  
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The Global Burden of Disease study estimates a more than 30% increase in deaths and 
disability attributable to PAD between 2005 and 2015, which is largely determined by 
population aging [17,18]. These numbers illustrate that PAD has become a global health 
problem [1]. In the next few years, due to the aging of the population, the disease will 
represent a sanitary and socioeconomic problem, for hypomobility, reduction of quality of 
life, risk of falls, hospitalizations and related costs [19,20]. Thus, redefining appropriate 
intervention standards will be necessary. 
 
2. PERIPHERAL ARTERY DISEASE: THE FACES OF THE DISEASE 
 
The spectrum of PAD presentation ranges from asymptomatic disease to IC, to CLI, and 
limb loss [1]. These different presentations of the disease are outlined in the two recognized 
clinical classifications, the Leriche-Fontaine and Rutherford classifications [21,22] (Table 1).  
Table 1. Leriche-Fontaine and Rutherford classification of peripheral artery disease[21,22] 
Leriche-Fontaine  Rutherford 
Stage 
Clinical 
presentation 
Signs and symptoms Physiopathology 
Clinical 
presentation 
Grade Category 
I 
Non-
symptomatic 
Occasional finding 
of aorto-iliac 
calcifications 
Atherosclerotic plaque, 
atherotrombosis 
Non-
symptomatic 0 0 
II A 
Mild 
Claudication 
ACD >200m 
Recovery time < 2 
minutes 
Discrepancy between 
muscular request and 
oxygen delivery 
Mild 
Claudication I 1 
II B 
Moderate-
Severe 
Claudication 
ACD <200m 
Recovery time > 2 
minutes 
Moderate discrepancy 
between muscular request 
and oxygen delivery 
Moderate 
Claudication I 2 
 
 ACD <100-80m 
Recovery time > 2 
minutes 
High discrepancy between 
muscular request and 
oxygen delivery 
Metabolic acidosis 
Severe 
Claudication 
I 3 
III 
Rest ischemic 
pain 
Rest pain Cutaneous hypoxia 
Tissue acidosis 
Rest pain 
II 4 
IV 
Ischemic 
ulcers, 
gangrene      
Trophic lesions Cutaneous hypoxia 
Tissue acidosis  
Ischemic neuritis 
Minor trophic 
lesion III 5 
 
 Necrosis or 
gangrenes 
Cutaneous hypoxia 
Tissue acidosis  
Necrosis 
Major trophic 
lesion III 6 
Abbreviations: ACD: Absolute Claudication Distance 
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3. RISK FACTORS, CLINICAL PICTURE AND DIAGNOSIS 
 
Different conditions may be responsible for the arterial insufficiency with IC or peripheral 
symptoms that occur while walking (Table 2); however, in most cases, PAD is a typical 
manifestation of atherosclerotic disease.  
Table 2. Pathologies potentially responsible of occlusive disease of lower limbs arteries. Adapted 
from Norgren et al. (2007)[3] 
Adventitial cyst of the popliteal artery 
Buerger’s disease / Thromboangitis obliterans  
Popliteal entrapment 
Primary vascular tumors 
Pseudoxanthoma elasticum 
Remote trauma or irradiation injury 
Takayasu’s disease 
Thrombosis of a sciatic artery 
 
Therefore, the risk factors responsible for its development are similar to those for coronary 
artery disease [1,23], which explains the overlap of PAD with the different vascular 
pathologies (coronary and cerebrovascular) in the same groups of patients [3,24]. In the 
REduction of Atherothrombosis for Continued Health (REACH) registry, 61% of PAD 
patients had concomitant coronary artery disease (CAD) and/or cerebrovascular disease 
[24,25]. 
Even if unmodifiable risk factors, such as age, gender, race and hereditary factors, may 
influence the atherosclerotic process, modifiable risk factors play an important role [6,9, 26-
28]. Smoking appears to be the most important risk factor for both the development and 
progression of PAD [29-35], as well as hypertension and high levels of circulating serum 
cholesterol [36,37]. Hyperhomocysteinemia is another risk factor for the correlations shown 
between IC progression and plasma homocysteine levels [38]. Diabetes is a condition that is 
strongly correlated with the development of peripheral arterial disease [39] and associated 
with worse outcomes, independent of other risk factors [2,40]. A 26% increase in the risk of 
PAD has been reported for diabetics for every 1% increase in glycated hemoglobin [41], as 
well a more aggressive manifestation of PAD than in nondiabetic patients. In these patients, 
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an early involvement of large and small vessels has been observed, with a more unfavorable 
evolution towards advanced stages of disease and negative vascular outcomes [42].  
At intermediate stages, the most common symptom of the presentation is IC, defined as a 
cramping leg pain that occurs during walking and is relieved after a short period of rest [1]. 
The symptom derives from the discrepancy between the oxygen demand of the working 
muscles and the possible oxygen supply, which is limited by the reduced blood flow. This 
insufficient oxygen delivery anticipates the activation of anaerobic metabolism in active 
muscles downstream of the lesions with an accumulation of lactic acid [2]. Considering that 
several arterial segments can be affected (e.g. the aorta and iliac, femoral, popliteal and lower 
leg arteries), the symptoms may affect the calf but also the foot, thigh and buttocks [1-3].The 
autonomy of walking free from ischemic pain, the so-called e free interval, may vary. 
Walking uphill or climbing stairs, conditions that increase the muscular energy cost and 
oxygen request, may anticipate the appearance of IC, with a further reduction of the free 
interval or symptom-free distance. The symptoms may also appear very early during walking 
until they become unsustainable, requiring a forced stop. Cramping pain regresses 
spontaneously after a certain period of time during which the patient remains standing, but it 
may require the need to rest in a sitting position. The recovery time usually does not exceed 
10 minutes [3]. 
Already at this intermediate clinical stage, in the presence of IC, PAD significantly 
diminishes maximal and pain-free walking capacity, affects the work capacity, restricts 
activity and mobility and considerably reduces health-related quality of life [43,44]. 
However, the walking disability in PAD is a complex pathophysiological phenomenon. 
Conflicting data are reported in PAD regarding the relationship between the severity of 
disease, in terms of ABI and calf blood flow, and functional parameters [45-51]. A mix of 
factors, including possible maladaptations due to progressive deconditioning discussed 
elsewhere, have been reported as potential drivers of limb discomfort and claudication [45]. 
Indeed, only 10% to 30% of PAD patients fall into the group of classic claudication, while 
20% to 40% report atypical leg pain [2] or a wide range of nonspecific symptoms in the lower 
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limbs, such as muscle fatigue, weakness and paresthesia. Many patients also report no 
exertional leg symptoms [52, 53]. Women with PAD may be more frequently asymptomatic 
or present with atypical symptoms [14].  
Patient-reported symptoms may therefore underestimate the presence of PAD. At 
intermediate stages, when peripheral symptoms are not present at rest, the inactivity of 
patients may lead them not to perceive claudication [3], leading to a delay in diagnosis. The 
same may occur in the presence of comorbidities associated with peripheral neuropathy: 
reduced pain sensitivity, obscuring the symptoms, makes the diagnosis of PAD more 
complex and delayed. 
In addition, the symptoms of IC can be misunderstood and confused with symptoms in the 
lower limbs derived from other morbid conditions [3] (Table 3). 
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Table 3. Differential diagnosis for leg pain in peripheral artery disease. Adapted from Norgren et al. 
(2007)[3] and Writing Committee Members et al. (2017)[23] 
Condition Location 
Characteristic 
Effect of Exercise/Rest 
Characteristics and prevalence 
Intermittent 
claudication 
Calf, Thigh 
and Buttock 
muscles, Foot 
Cramping, aching 
discomfort, severe pain 
on exercise 
Reproducible onset 
Recedes quickly 
Atypical limb symptoms on exercise are 
possible 
Common prevalence 
Symptomatic 
Baker’s cyst 
Behind knee, 
down calf 
Swelling, tenderness 
With exercise 
Also at rest 
Not intermittent 
Rare prevalence 
Venous 
claudication 
Entire leg, 
worse in calf 
Tight, bursting pain 
after walking 
Recedes slowly 
History of iliac-femoral deep vein 
thrombosis; edema; signs of venous stasis 
Possible relief with elevation 
Rare prevalence 
Chronic 
compartment 
syndrome 
Calf muscles 
Tight, bursting pain 
After much exercise 
Recedes very slowly 
Muscled athletes 
Possible relief with rest 
Rare prevalence 
Spinal 
stenosis 
Often bilateral 
Buttocks, 
posterior leg 
Pain and weakness 
May mimic claudication 
Variable relief 
Possible relief with lumbar spine flexion 
Worse with standing and extending spine 
Common prevalence 
Nerve root 
compression 
Radiates down 
leg 
Sharp lancinating pain 
Induced by sitting, 
standing, or walking 
Often present at rest 
History of back problems; 
Possible relief with change in position 
Common prevalence 
 
Hip arthritis 
Lateral hip, 
thigh 
Aching discomfort after 
variable degree of 
exercise 
Recedes slowly 
History of degenerative arthritis 
Symptoms variable; 
Possible relief with not weight bearing 
Common prevalence 
Foot/ankle 
arthritis 
Ankle, 
Foot arch 
Aching pain 
After variable degree of 
exercise 
Recedes slowly 
Symptoms variable; may be related to 
activity or present at rest 
Possible relief with not weight bearing 
Common prevalence 
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In general, the diagnosis of PAD based on the history and physical examination may not be 
a reliable tool for the identification of disease [2], therefore a more accurate assessment, by 
means of instrumental evaluations is necessary for the diagnosis [23] (Table 4). 
Table 4. Factors useful to recognize the presence of peripheral artery disease. Adapted from Writing 
Committee Members et al. (2017)[23] 
Age 
    Risk factors 
Age > 65 years 
Age 50-64 and more risk factors  
(diabetes, hypertension, hyperlipidemia, history of smoking, family 
history of peripheral artery disease) 
Age < 50  
diabetes and > 1 risk factor  
Atherosclerotic 
Comorbidities 
Other vascular bed(s) with atherosclerotic disease (coronary, carotid, etc.) 
Reported function 
Impaired Walking function  
Atypical leg symptoms  
Claudication  
Ischemic rest Pain 
Objective examination 
(lower limbs) 
Abnormal pulse  
Vascular (femoral) bruits  
Non healing wound 
Gangrene  
Maneuvers (e.g. foot elevation) 
  
Measurement of the ABI at rest is one of the procedures most frequently used for the 
diagnosis of PAD for its high sensitivity and specificity [54,55]. ABI measurement, 
performed in a few minutes with a portable Doppler and a sphygmomanometer [23], is 
obtained by determining the systolic blood pressures at the arms (brachial arteries) and ankles 
(dorsalis pedis and posterior tibial arteries) in the supine position. The ABI of each leg is 
calculated by dividing the higher of the dorsalis pedis pressure or posterior tibial pressure by 
the higher of the right or left arm blood pressure [56]. ABI values lower than 0.9 depose for 
the diagnosis of PAD (Table 5). 
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Table 5. Ankle-brachial index values classification. Adapted from Aboyans et al. (2012)[56] 
ABI Clinical interpretation 
≥ 1,4 Above-normal; non-compressible vessels 
1,4 < ABI < 0,9 Normal 
0,9 ≤ ABI < 0,7 Mild peripheral artery disease 
0,7 ≤ ABI < 0,5 Mild-moderate peripheral artery disease 
≤ 0,5 Severe peripheral artery disease 
Abbreviations: ABI: Ankle-brachial index 
However, the ABI has some limitations [56]. Some patients could present IC in the presence 
of ABI values at rest that are considered normal (> 0.9); in this case, measurement of the ABI 
after the execution of a treadmill walking test can improve the sensitivity of a method: a 
decrease in ABI exceeding 15-20% measured immediately following the walk test supports 
the diagnosis of PAD [3]. Furthermore, in certain groups of patients (mostly with diabetes or 
severe renal impairment), ABI may not be reliable as a diagnostic measure. In these patients, 
because of the severe calcification of the medium tunica, the vessel can in fact be 
uncompressible by the sphygmomanometer sleeve, giving incorrect results. Typically, these 
patients have abnormally high ABI values (> 1.4); therefore, other noninvasive diagnostic 
techniques are necessary to define the presence or absence of PAD [3]. Furthermore, in some 
patients, the measurement of ABI may also be incorrect in the presence of obstructive lesions 
to the subclavian or axillary arteries, or subclavian artery stenosis [57-59], which affect the 
systolic blood pressure recording. For this reason, it is important to measure the systemic 
arterial pressure in both upper limbs and use the highest value for an accurate ABI 
calculation. An interarm blood pressure difference of >15 to 20 mmHg is abnormal, 
suggestive of subclavian (or innominate) artery stenosis and a marker of increased 
cardiovascular risk [60,61].  
Other measures may support or substitute ABI, when this is considered unreliable. The toe-
brachial index (TBI) is used to establish a diagnosis of PAD in the setting of non-
compressible arteries (ABI >1.40) and may also be used to assess perfusion in patients with 
suspected CLI [23]. Segmental lower extremity blood pressures and Doppler or 
plethysmographic waveforms may offer information in terms of the localization of the 
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anatomic segments affected by PAD. Additional perfusion assessment measures (e.g., 
transcutaneous oxygen pressure) or skin perfusion pressure can also be performed in selected 
cases [22, 23, 62-63]. In recent years, muscular near-infrared spectroscopy (NIRS) has also 
been employed in investigations of PAD. When NIR light propagates through biological 
tissue, a portion is absorbed and mostly scattered by the tissues, which can be recollected by 
the detector. The intensity of the recollected light provides information about oxy- and deoxy-
hemoglobin concentrations as determined by spectral analysis. This technique allows the 
noninvasive assessment of muscle metabolism both in static and dynamic conditions for 
experimental purposes [49-52].  
However, the most diffuse and available diagnostic technique, which is useful in the 
instrumental diagnosis of PAD, is the Echo-Color-Doppler examination, which allows both 
visualization of the location and extent of the stenotic-obstructive lesions, and the 
characteristics and directions of blood flow.  
More sophisticated and invasive instrumental techniques are mainly used to plan a surgical 
revascularization procedure, such as digitized image subtraction angiography, which allows 
one to precisely define the anatomy of the vessel, and Angio-CT and Angio-MR, which allow 
the most refined analysis of the anatomical relationships between the structures.  
The diagnostic pathway of PAD according to the most recent AHA guidelines is reported in 
Figure 1.  
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Figure 1. Diagnostic pathway of peripheral artery disease according to the most recent American 
Heart Association guidelines. Adapted from Olin et al. (2016)[2] 
 
Abbreviations: PAD, peripheral artery disease; ABI, ankle-brachial index; TBI, toe-brachial index 
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4. PERFORMANCE OF THE PATIENT WITH PERIPHERAL 
ARTERY DISEASE  
 
Objective determination of functional capacity is an important topic at intermediate stages of 
disease, when the patient is mainly affected by a walking disability. However, in common 
clinical practice, walking ability is often simply assessed by asking patients to report the 
distance covered before they are forced to stop. These data have been considered poorly 
reliable and inaccurate, both when reported by patients and when estimated by vascular 
surgeons [64,65], or sufficiently reliable [66]. However, an objective assessment is 
recommended [3,23]. The functional evaluation can indeed support the diagnostic phase, 
providing additional elements for patient stratification and the definition of the degree of 
disability. It may also contribute to determining the most appropriate therapeutic strategy to 
propose to the patient. 
Validated functional assessment protocols include treadmill tests [67], corridor tests [68], 
and patient-reported symptom measurement questionnaires. The most commons tools are 
reported in Table 6. The development of new technologies also offers the possibility of in 
vivo measurements of the functional capacity of patients within their daily activities [69-71].  
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Table 6. Measurements of functional status and outcome measures of execise therapy in patients with 
peripheral artery disease. Adapted from Treat-Jacobson et al. (2019)[77] 
 Type Utility Primary Measure 
Detects Treatment 
Effect 
Graded 
Treadmill test 
Exercise test 
Objective measure 
of peak 
exercise 
performance 
 
Peak walking time on 
a treadmill  
Exercise training 
Pharmacotherapy 
Revascularization 
Intermittent 
pneumatic 
compression 
6-MWT 
6-minute walk test 
Exercise test 
Objective measure 
of maximal 
walking distance, 
measured in a 
corridor 
Maximal distance 
walked in 6 min  
Exercise training 
Supplement 
Intermittent 
pneumatic 
compression 
Mobility loss 
Treadmill test 
Assisted by 
technology 
(TcPO2-NIRS) 
Exercise test 
Objective measure 
of dynamic muscle 
(calf, foot) oxygen 
discrepancy 
Degree of muscle 
perfusion (Area-under 
curve) of  
Oxy-hemoglobin 
Exercise training 
Pharmacotherapy 
Revascularization 
Intermittent 
pneumatic 
compression, Elastic 
compression 
Accelerometer 
Physical 
activity 
monitors 
Objective measure 
of activity during 
daily life 
Wearable device  Exercise training  
MOS SF-36 
MOS SF-12 
Medical Outcomes 
Study Short-Form 
Questionnaire 
(General) 
Health-related 
quality of life  
Physical and mental 
function  
 
Exercise training 
Pharmacotherapy 
Revascularization 
EQ-5D  
EuroQOL 5D 
 
Questionnaire 
(General) 
Functional status 
and health-related 
quality of life 
State of health and 
function  
 
Exercise training 
Revascularization 
WIQ 
Walking 
Impairment 
Questionnaire 
Questionnaire 
(specific) 
Functional status  
Distance, speed, 
stairs, and 
claudication severity 
Exercise training 
Pharmacotherapy 
Revascularization 
VascuQoL  
Vascular Quality 
of Life 
Questionnaire 
Questionnaire 
(specific) 
Functional status 
HRQOL Pain, 
symptoms, activities, 
emotional, social 
 
Exercise training 
Revascularization 
PAQ  
Peripheral Artery 
Questionnaire 
Questionnaire 
(specific) 
Functional status 
and health 
satisfaction 
Physical function, 
satisfaction 
with care 
Exercise training 
Revascularization 
Medical therapy 
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PADQOL  
Impact of 
PAD on Quality of 
Life Questionnaire 
Questionnaire 
(specific) 
Health-related 
quality of life 
Symptoms/physical 
limitations, fear/ 
uncertainty, social 
interactions, self-
sense, feeling states, 
adaptation 
Exercise training 
4.1. Treadmill testing 
 
Treadmill tests, used for years in patients with PAD, are still considered the gold standard 
for the assessment of ambulatory capacity in patients with IC and to measure changes in 
walking endurance and peak exercise capacity in response to exercise interventions in 
patients with PAD [72-77]. Treadmill testing has the advantage of being conducted in a 
standardized setting in which the speed and grade of the treadmill are increased at the same 
magnitude for each test [75]. These tests, combined with the measurement of ABI before and 
after exercise, represent a useful diagnostic tool to confirm or exclude the presence of PAD 
in patients with nonspecific lower limb disorders. Moreover, the American Heart Association 
(AHA) and the American College of Cardiology (ACC), the American College of Sports 
Medicine, and the American Association of Cardiovascular and Pulmonary Rehabilitation 
recommend an exercise treadmill test prior to exercise training to evaluate baseline walking 
capacity and to assess the degree of exercise limitation (Class I; level of evidence B). [23,78]. 
The parameters derived from the treadmill tests are the Initial Claudication Distance (ICD) 
or Pain Free Walking Distance (PFWD) or Claudication onset time (COT) and the Absolute 
Claudication Distance (ACD) or Maximal Walking Distance (MWD). The first ones 
correspond to the distance walked to the appearance of the first symptoms of claudication in 
the lower limbs, while the second one is the maximum distance (or time) that can be walked 
before the forced stop, when ischemic leg symptoms, fatigue, or other symptoms prevent 
patients from continuing [77]. 
There are various protocols used for this purpose in the clinical setting. The so-called constant 
load tests are performed at fixed speed and slope values generally set between 2 and 4 kmh-
1 and between 0 and 12% [67], respectively. Incremental protocols, originally adopted by 
cardiology studies [79], are characterized by the maintenance of a constant walking speed 
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with load variations obtained through progressive slope increases [80]. Most graded 
protocols in fact have a constant speed and increase the grade every 2 to 3 minutes to a 
symptom-limited maximal (or peak) walking time [77]. The graded Gardner-Skinner 
treadmill exercise test is a protocol that is frequently used in randomized trials to assess the 
functional effects of therapeutic interventions in PAD [80]. In this test, participants walk on 
the treadmill at 2.0 mph with a grade of zero at the beginning, which is gradually increased 
by 2% every 2 minutes. A modified version of this test for patients with poorer performance 
is based on an initial speed of 0.5 mph and a grade of zero, which is increased by 0.5 mph 
every 2 minutes until 2.0 mph is achieved, and then by 2% every 2 minutes [77,80]. 
The graded treadmill tests, which allow objective grading of the disability of PAD [80-82] 
with a better test-retest reliability than constant-load treadmill testing, represent the preferred 
method of treadmill testing in randomized trials of PAD [67-68,81-83]. Maximal walking 
capacity assessed by a graded treadmill test is frequently employed as a primary endpoint in 
randomized-controlled trials (RCTs), and it is sensitive to change with a variety of 
interventions [1]. The treadmill test also enables the quantification of changes in functional 
parameters in response to exercise interventions [68]. A mean improvement of peak walking 
time (PWT) ranging from 3.4 to 4.6 minutes and changes in COT ranging from 1.65 to 2.2 
minutes [64,66,69] have been reported after a treadmill-based supervised exercise therapy 
(SET) program, with respect to a control group [77]. The treadmill-based measures, which 
were correlated with mortality and the risk of major cardiovascular events [84], also show 
limitations. Variations in the measured parameters ranging from 17% to 26% [85-87] were 
observed in the studies also in absence of any therapeutic intervention, for a learning /placebo 
effect derived from repeating treadmill tests at baseline and follow-up [75]. 
The treadmill walking during a laboratory measurement is influenced by the speed and slope 
imposed by an operator, and therefore, the functional capacity may not correspond to the 
actual disability experienced by patients on the ground and within their daily activities 
[68,88-89]. 
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From the methodological perspective, different treadmill protocols have been used in the 
different trials, making it difficult to compare the results obtained in some studies. Other 
authors have validated protocols with progressive increases in speed in the absence of a slope 
or combinations of increments between speed and slope [90,91].  
In general, individualized ramp protocols, which begin at low work rates and have low work 
rate increments per stage may be useful among patients with severe claudication symptoms 
[45]. Purposely, a novel test based on level walking and incremental speed [92] is was based 
on a starting speed fixed at 1.5 km/h with small increments of 0.1 km/h every 10 meters up 
to patient exhaustion due to muscle pain or fatigue. The test aims to determine a critical 
walking speed during a more natural level walking that may be useful to guide the training 
at home, rather than a generic distance at an increasing slope. The parameters obtained are 
the speed at the onset of symptoms, the so-called Pain Threshold Speed (PTS), and the 
Maximal Speed (Smax) [92]. A disadvantage of this protocol in comparison to traditional 
ones is that the load may not be sufficiently high to evoke pain and therefore to observe and 
quantify symptoms in case of mild claudication. The test is therefore more useful for patients 
with moderate-severe disease and very early claudication.  
 
4.2. Corridor tests 
 
Protocols for patient’s assessment based on ground walking are also available in the 
literature. These protocols more closely simulate walking activity during daily life [68,94-
100], overcoming some previously reported limitations of the treadmill tests. These tests also 
enable evaluation of the patient in structures not equipped with ergometers and specialized 
personnel [74]. These tests have been specifically validated for PAD or simply mediated by 
tests already used for the assessment of functional capacity in other patient populations as for 
patients with chronic respiratory diseases [101,102].  
The 6-minute walk test (6MWT) [101,103] is carried out in a corridor, where a straight 
course, possibly of approximately 30 meters, is marked on the ground. The subjects are 
instructed to walk back and forth with the aim of covering the maximum distance possible in 
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6 minutes. At the onset of the IC, the patient informs the operator and continues to walk until 
the symptom becomes unbearable. Participants are allowed to stop and rest - and sit down in 
a chair while resting - and resume the test as soon as possible. During the rest period, the 
stopwatch continues to run. At the end of the 6 minutes, the total distance walked in the 
6MWT and distance to the appearance of symptoms (PFWD) are recorded. The 6MWT is a 
validated measure of walking endurance, with a response to therapeutic interventions and not 
associated with a learning effect when repeated testing is performed. It also predicts rates of 
mobility loss and mortality [68,74,77,96-99,104-105]. Declines in 6MWT performance have 
also been linked to clinically meaningful outcomes in people with PAD [100, 106-108] and 
in elderly people without PAD [109]. A clinically meaningful change in the 6MWT distance 
has been defined as 20 m (small change) and 50 m (large meaningful change) [77]. An 
increase from 41 to 53 m were reported following a structured home-based walking exercise 
program in comparison to a control group not exercising [97,99].  
Another corridor test derived from the assessment of other chronic diseases is the Incremental 
Shuttle Walk test [102]. The patient is instructed to walk from one side to the other of a 10-
meter-long space at a progressively increasing speed paced by an acoustic signal with the 
aim of covering the distance between the two cones before the next audio signal. The test is 
considered terminated when the patient fails to complete the distance within the pre-
established time. A corridor incremental test has also been proposed to determine the pain 
speed in the patient with PAD during a test at progressively increasing walking speeds [110]. 
The patient is accompanied during the test by an operator who, with the help of a stopwatch 
or a metronome, dictates the walking speed by making increments every 10 m up to the 
maximal speed tolerated. The operator notes the symptoms promptly reported by the patient. 
As per the previously described treadmill test, the purpose of the test is both to determine the 
degree of disability and to obtain the individual critical walking speed, specifically assessed 
for use in home training. 
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4.3. Physical activity monitoring 
 
More recently, free-living physical activity in daily life [85,86] has become a measure of 
growing interest to assess the mobility of patients and their lifestyle. The assessment is 
performed using wearable technology such as activity monitors in the form of wristbands or 
other types of accelerometers [111]. These tools can help to define the autonomy of the 
patients and to quantify activity at home before and after therapeutic interventions. Finally, 
in patients with IC, the aim of each treatment strategy should be the increase in spontaneous 
activity by a gain of walking autonomy. 
The pedometer is the simplest device, capable of measuring the number of steps completed 
in a day and deriving the distance traveled and energy cost. Pedometers were validated in 
patients with PAD [69] and used in RCTs as an outcome measure [87,112-114]. 
Accelerometers measure accelerations on the horizontal and vertical plane and convert the 
collected movements into an estimate of the energy cost, reflecting the level of activity 
performed. The validity of these instruments in PAD has been tested [69] and related 
measures included as secondary outcome measures in clinical trials [115]. Modern devices 
allow the differentiation between the various positions of the subject and quantification of 
the time spent in sedentary positions (sitting or lying down), standing and walking, with 
greater precision in the measurements of daily physical activities in patients with IC [71]. 
Recently, monitoring of physical activity with the Global Positioning System (GPS) has also 
been applied in patients with PAD [116], with an exact determination of the spontaneous 
walking time and distance as well as patterns and walking habits of PAD patients during 
leisure time [70]. A combination of GPS, which requires adequate satellite coverage, and 
accelerometers can be more precise in evaluating movements within the entire range of daily 
activities [116]. Both physical activity monitoring tools and GPS systems are incorporated 
into the latest generations of smartphones, making these technologies available to a larger 
group of patients. The use of smartphones for remote supervision of exercise programs was 
tested in a cardiological rehabilitation setting [117] and recently in PAD home-based walking 
programs where the activity carried out was monitored by these devices [118]. The 
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limitations derive from the requirement of wearing specific equipment for this measure, 
resulting in adherence problems. The device might be used by another member of the family 
with an unreliable assessment of the activity. The measure may represent a possible intrusion 
into privacy. In addition, the memory of the device is variable, and therefore, strategies for 
storing data must be established. Finally, further validation and large-scale application of 
these instruments are needed in patients with PAD for comparison with traditional 
measurement systems such as treadmill tests. 
 
4.4. Exercise testing assisted by technology 
 
Transcutaneous oximetry assesses the partial pressure of oxygen in mmHg. It is mainly used 
to determine baseline values of skin perfusion with the patient in the supine position; 
however, the reproducibility of exercise transcutaneous oximetry has also been reported for 
the dynamic study of regional blood flow [119]. 
Near infrared spectrometry is a tool that enables the assessment of deep tissues perfusion 
[120] under static and dynamic conditions. This technique, which has been previously 
described, allows the study of the muscle in terms of oxygenation as well as oxygen 
extraction at rest and during motor tasks (e.g., while walking). This technology, which does 
not require a special infrastructure and uses relatively low-cost portable instruments, has 
potential for the dynamic study of oxygen delivery and deconditioning related to the 
disability and therefore has been utilized for functional and diagnostic tests in PAD patients 
[122-124].  
 
4.5. Testing patients unable to walk 
 
In the presence of severely limiting or contraindicating pathologies that prevent the execution 
of dynamic tests, alternative methods of evaluation have been proposed. An evaluation 
protocol is based on the plantar flexion of the foot, which is correlated with the treadmill test 
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or finger flexion [125]. A further method consists of producing ischemization by inflating a 
thigh-level cuff to a pressure higher than the systolic value, maintaining this pressure for 3-
5 minutes and evoking the related subsequent hyperemia. The reduction of ankle pressure 
within 30 seconds after the cuff is released corresponds approximately to that observed 1 
minute after the onset of claudication [3]. 
More recently, a toe-flexion test assisted by NIRS has been validated to quickly and 
dynamically assess the perfusion of the more distal part of the foot [126,127]. 
 
4.6. Measurements using questionnaires 
 
Validated and feasible questionnaires measure the functional status and health-related QoL 
of people with claudication, assessing the subjective perceptions of their ability to function 
in daily life and their well-being before and after an exercise intervention [77]. Changes in 
functional capacity assessed by a questionnaire or measured using the treadmill are equally 
considered [3]. Moreover, the measures derived from questionnaires, when performed in 
addition to objective measures of walking ability [23], may determine whether a specific 
therapy able to objectively increase patient’s exercise performance is also associated with its 
perception in daily life [23,77].  
The most widely used questionnaire among PAD patients is the Walking Impairment 
Questionnaire WIQ [128,129]. The WIQ [130] is a disease-specific questionnaire widely 
used to assess the ability of patients with IC to walk, which collects information on distances, 
speeds and capacity to climb stairs. It allows an estimation of the ambulatory capacity on the 
basis of the symptoms reported by the patient in various motor tasks, evaluating claudication 
severity and the presence of other (e.g., non claudication) symptoms that potentially limit 
walking [77,130]. Doubts concerning the accuracy and validity of the WIQ questionnaire 
[131-132] have been dissipated by studies confirming its accurate estimation of the daily 
walking ability of patients with IC [66, 89] and supporting its capacity to improve mortality 
risk prediction models [133]. The questionnaire, which has been translated into and validated 
in more than 50 languages, has been used to evaluate changes in community-based walking 
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ability following an exercise program [134-135], vascular stenting, [136-137] and 
pharmacological agents [77]. The score ranges from 0 to 100, with higher scores indicating 
better community-based walking ability. 
Quality of life is an important issue to be considered and assessed. The indices commonly 
used in clinical practice to assess the severity of the disease, such as ABI or some functional 
assessment tests, may poorly correlate with the overall negative impact of the disease on the 
patient. Quality of life is reduced in patients with PAD due to lower extremity pain and 
activity restriction [45, 138], which is not always fully perceived or considered by the 
physician [139]. Quality of life has been defined as the degree to which people perceive 
themselves physically, emotionally and socially. In a general sense, QoL is what makes life 
worth living [140]. The QoL of the patient with PAD is therefore an aspect to be investigated, 
as it is greatly reduced compared with the healthy population of the same age and sex [43,141-
142]. The importance of this aspect means that QoL is indicated as an outcome in clinical 
trials in cardiovascular diseases [23,143].  
The perception of the state of health is linked both to the reduction of autonomy, the 
continuous perception of pain, or the inability to perform normal work, and it is linked to the 
patient's lifestyle and social interactions. The concept of QoL is therefore intended as a 
multidimensional construct that includes different dimensions: physical, psychological and 
social, which are subjectively evaluated. A reduced QoL has been associated with an increase 
in the clinical course and a poor prognosis [144] and with the appearance of depression 
particularly in certain groups of patients such as young women [145]. The evaluation of QoL 
therefore helps to better understand the basic condition and the clinical evolution of PAD and 
its treatment. Thus, at intermediate stages of PAD, any procedural treatment should be aimed 
at reducing the symptoms of the lower limbs to improve the perception of QoL, thus success 
should not be evaluated only in terms of a good instrumental result (hemodynamic measures, 
functional capacity, mobility) but also in light of its consequences on patients' daily life [146]. 
QoL assessment tools [143, 147-148] available to graduate the patient's perception of 
disability can be filled out directly by the patient himself or administered through interviews. 
Fabio Manfredini, MD 
 
 63 
These questionnaires may cover a wide spectrum of conditions present in various diseases 
(generic questionnaires) or evaluate the impact on QoL of specific aspects of the disease 
under study (specific questionnaires). 
Specific questionnaires offering PAD-specific measures are available. They assess 
limitations in walking or QoL as well as patient-reported perceptions after exercise 
interventions. Validated tools are the Vascular Quality of Life Questionnaire (VascuQoL), 
[149] the Peripheral Artery Questionnaire (PAQ), [150] and the Impact of PAD on Quality 
of Life Questionnaire [151]. The VascuQoL, developed in 2001 [149] and translated into 
several languages, has been appreciated for patients with IC [152-153] and used to assess 
outcomes of interventions for patients with PAD, including exercise and revascularization 
[77]. It consists of 25 items, divided into 5 domains: activities performed (8 items), symptoms 
(4 items), pain (4 items), emotional status (7 items), social role (2 items). Each question has 
a Likert response scale from 1 to 7, from which a total score is generated for the questionnaire 
and a score for each domain, with values ranging from 1 (worst quality of life) to 7 (best). 
The PAQ is a disease-specific health status questionnaire for patients with PAD that assesses 
both functional status and QoL [150,154]. The PAQ proposed in 2004 [150,155] is composed 
of 20 questions to determine the physical limitation, the symptoms (frequency, severity and 
modifications), the social function and the satisfaction of the received therapeutic treatment. 
The score obtained from the sum of the scores for each single domain is converted into a 
scale from 0 to 100, where a higher score corresponds to reduced physical limitations, 
improved QoL and greater satisfaction from the treatment received. The PAQ has been used 
to assess outcomes in revascularization studies and for a study comparing exercise 
rehabilitation and endovascular procedures [87]. The Impact of PAD on Quality of Life 
Questionnaire [151] is a 38-item questionnaire with 5 subscales assessing the impact of the 
disease on multiple dimensions of life including social relationships and interactions, 
symptoms and limitations in physical functioning, fear and uncertainty. The scores range 
from 0 to 100, with higher scores indicating better health-related QoL [77].  
The Claudication Scale (CLAU-S), developed in 1985, has been progressively modified, with 
a number of questions reduced from 89 to 47 and a number of domains from 9 to 5 (daily 
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life, social life, pain, apprehension related to the disease and "state of mind"). The score 
ranges from 0 to 100, where the highest scores represent a better QoL [156]. The Sickness 
Impact Profile-Intermittent Claudication is a validated tool [157] adapted from a generic 
questionnaire Sickness Impact Profile for the evaluation of QoL. Twelve questions have been 
selectively extracted from the categories of ambulation, mobility, sleep and rest, home 
management, social interaction, and alarm status. The total score, represented by the sum of 
the questions, is between 0 (or best QoL) and 12. Other specific tools available for the 
assessment of Quality of Life are represented by the ARTEMIS Scale [158] and the 
Peripheral Arterial Occlusive Disease 86 Questionnaire [159]. 
Generic QoL questionnaires that are applicable to large populations and not dependent on a 
disease or treatment are also commonly used. They offer the possibility to compare data for 
patients with different pathologies and with healthy subjects; however, the absence of focus 
on a specific disease may not be sufficiently sensitive to detect clinically significant changes 
[160]. The Short-Form (SF)-36 [161] or SF-12 [162] and the Euro-Qol-5D [163] are the most 
common general health status or health-related QoL questionnaires used to evaluate 
outcomes of exercise therapy for patients with PAD [77]. The Medical Outcomes Study SF-
36 [161] includes 36 items that cover different aspects of quality of life grouped into 8 
domains, each with its own score (physical activity, physical role, physical pain, general 
health, vitality; emotional role; social activities; mental health). The results can then be 
summarized in two summary scales, for the Physical Sphere and for the Mental Sphere. The 
scores for each domain can vary between 0 and 100 (best possible perception of QoL). The 
questionnaire has been widely used in patients with PAD [164-168] in some cases without 
consistent improvements following some exercise programs [96,169]. More recently, an 
abbreviated version of his questionnaire, the SF-12 questionnaire, has been produced [161], 
which consists of only 12 items derived from 6 of the 8 scales of the SF-36 questionnaire. 
Ten questions are able to explain at least 90% of the variance of the two main scores (physical 
and mental scale) of the SF-36, and 2 more questions provide a complete description of the 
8 scales in the SF-36, with satisfactory results [170]. 
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The general questionnaire EuroQol [163,171] investigates 5 dimensions: mobility, self-
care, habitual activities, pain, and anxiety/depression, and it includes a visual-to-analog 
scale from 0 to 100 where the patient reports the perceived level of their health status. The 
tool has been used in trials of revascularization and exercise therapy in PAD patients 
[152,172]. 
The Nottingham Health Profile [173] measures the patient's disability based on 38 questions 
divided into 6 domains: mobility, pain, sleep, energy, social isolation and emotional state. A 
dichotomous response system (yes / no) is used, with a score for each section between 0 
(better QoL) and 100. The questionnaire is indicated for surveys in subjects with disability. 
Questionnaires represent an important complement to objective measures of improvement 
after walking exercise interventions, even if they may not congruently change with the 
functional (treadmill or walking) tests [87,97,168]. Moreover, for research purposes, a 
combination of generic and specific questionnaires should be useful [174]. 
 
5. THE NATURAL HISTORY OF THE PATIENT  
 
Peripheral artery disease does not generally show an aggressive behavior, even if 
noncessation of the tabagic habit or the presence of diabetes can significantly increase the 
risk of disease progression to more advanced stages [23,42]. Total limb amputation 
represents an uncommon outcome as a result of IC, since only 1 to 3.3% of patients with IC 
require major amputation after a period of 5 years [3]. In a long-term longitudinal study, the 
cumulative risk of a 10-year aggravation of the condition with the development of rest pain 
or trophic lesions was 30% and 23% respectively, with a cumulative frequency of major or 
minor amputations of less than 10% [175]. Conversely, due to the ongoing generalized 
atherosclerotic process, the risk of appearance of fatal and noncardiovascular events is high 
[1]. Considering patients at each stage of PAD, the risk of cardiovascular morbidity and 
mortality is approximately 3 times greater than their peers even in the setting of asymptomatic 
disease [2,54,176]. At 5 years, 1 out of 5 patients with PAD is affected by a nonfatal 
cardiovascular event, with a rate of death of 15% to 20%, mostly due to cardiovascular causes 
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[1-2,8,23,177]. The mortality risk rises at 50% within 10 years, especially for myocardial 
infarction (60%) or stroke (12%), according to some authors [178-180]. Therefore, only a 
limited proportion of patients with PAD (20-30%) die from non-cardiovascular causes. Given 
these data, correction for risk factors such as smoking, dyslipidemia and hypertension, 
control of diabetes and thrombotic risk, and initiation of physical activity are crucial actions 
for the patient with IC, in the presence of a widespread pattern of systemic atherosclerosis.  
PAD therefore represents an atherosclerotic marker associated with an elevated risk of 
cardiovascular events in both symptomatic and asymptomatic subjects [45,181]. Systematic 
reviews and meta-analyses confirm that the presence and severity of PAD, defined by 
measurement of the ABI [3], are related to a risk of unfavorable events. A low ABI is 
independently associated with increased CAD and clinical cardiovascular disease risk, after 
adjusting for Framingham Risk Score factors [182]. A meta-analysis of over 48,000 
participants in population-based cohort studies showed a 2-fold risk of death, cardiovascular 
death, and major coronary events in the presence of a low ABI (defined as < 0.90) at all 
ranges of the Framingham Risk Score versus those with a normal ABI [45,54,183]. In 
addition, the severity of disease, defined by lower ABI values, as well as the decrease in ABI 
values, are associated with increased numbers of cardiovascular events and greater functional 
decline [2,44,106,108,184-191]. The presence of IC amplifies the cardiovascular risk: the 
annual incidence of nonfatal myocardial infarction is 2-3%, and the risk of angina pectoris is 
approximately 2-3 times higher than that of subjects of the same age [3]. Moreover, the 
progression of IC to CLI increases the rate of negative outcomes to 10% for fatal 
cardiovascular events at 1 year and 25% for limb amputations [1,2,192]. Therefore, IC, which 
is responsible or the negative outcomes associated with progressive and significant 
reductions of mobility, represents a marker of severe generalized cardiovascular disease 
[24,193-194] and an independent predictor of mortality [195]. In the presence of IC, even in 
the absence of hemodynamic deterioration, the patient shows a progressive reduction of 
ambulatory function, physical activity, physical function and calf blood flow [196]. A slower 
walking speed and a self-restriction of activity are also observed to prevent the occurrence of 
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symptoms and reduce leg pain [45,197-198]. Consequently, reduced physical activity levels 
during daily life measured with a vertical accelerometer and greater sedentary hours per day, 
have been associated with higher rates of more rapid functional decline and reduced assessed 
mobility [199-201]. The reduced health-related QoL in PAD also increases the prevalence of 
depression, which is largely related to leg symptoms [148, 202]. A progressive mobility loss 
make patients unable to walk for 6 minutes in comparison to individuals without PAD [44-
45,203-204]. This negative transition is well-documented by the Walking and Leg 
Circulation Study [189]. In comparison to subjects with a normal ABI, PAD patients with an 
ABI from 0.70 to 0.90 or with an ABI < 0.50 were 2.7 and 11.7 times unable to walk for 6 
minutes without stopping, respectively. At the 5-year follow-up, compared with people 
without PAD, the two PAD groups were 3.2 and 4.2 times more likely to become unable to 
walk one-quarter of a mile or walk up 1 flight of stairs without assistance, independent of 
age, comorbidities, and other confounders [189]. The study also showed that also patients 
with PAD without reported exertional leg symptoms [44,204] were exposed to a functional 
impairment and functional decline with a higher risk of mobility loss [189,191]. Progressive 
histological, metabolic and electrophysiological changes in the lower limb muscle induced 
by the chronic circulatory insufficiency may explain the physical decline observed in PAD 
patients, as excellently reviewed by Hamburg et al. [45]. These changes include myofiber 
damage, mitochondrial disfunction and inefficient microcirculation together with an altered 
fiber composition [45]. A reduced number of type I and IIa fibers and an increased number 
of type IIb fibers [205] have been reported, as well as the presence of oxidative fibers with 
reduced muscle oxidative capacity [206]. Signs of oxidative stress produced by reactive 
oxygen species [207-211], altered mitochondrial metabolism [212] with possible related 
reductions of angiogenesis and vascular regeneration [213] and peripheral nerve function 
damages have also been described [214-215]. Moreover, PAD patients with IC also suffer 
from a loss of muscle mass with sarcopenia [45] favored by deconditioning, which contribute 
to further reductions of muscle mass and affect the peripheral circulation [216-218]. This 
general maladaptive condition is associated with metabolic alterations, including muscle 
insulin resistance [219] and a higher risk of developing clinical diabetes [220-221]. 
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Sarcopenia in PAD is also associated with functional changes, such as alterations of the 
walking pattern with variations in muscular electrical activity, reduced speed of displacement 
[222], biomechanical changes in the movements of the hip, knee and ankle joints [223-224], 
reduced length of the step with greater energy costs and lower walking economy [225]. 
This combination of early muscular fatigue and reduced walking efficiency contribute to the 
vicious cycle of illness-disability-deconditioning with a reduction in spontaneous activity. 
This situation decreases the control of risk factors [226], worsens exercise tolerance and 
cardiovascular response [227-228], and reduces protective vascular factors (e.g., a reduced 
nitric oxide bioavailability). A number of studies have previously demonstrated impaired 
endothelial vasodilator responses in PAD [207-208,212]. This condition, predictive of a 
higher risk for cardiovascular events [213,229], may generate peripheral arterial 
vasoconstriction [230-232], reduced augmentation of blood flow during exercise [233,234] 
and vascular stiffness. These factors have been associated with self-reported and assessed 
walking disability [48-49,51,235-236]. Again, in this vicious cycle, microcirculatory 
dysfunction also affects limb function in patients with PAD. Angiogenesis and collateral 
formation, favored by physical activity [237-238], are inadequate due to inactivity. The 
endothelial progenitor cells, which are limited in number and function by risk factors and 
considered to be predictors of cardiovascular events [239-240], are reduced in number in 
PAD and correlated to the ABI [241] and mobility in ESRD patients [242]. These factors in 
PAD are associated with higher rates of cardiovascular events and death [76,133,199,243-
247], and in a group of PAD patients with a greater decline in ABI over time [248]. In 
contrast, a lower mortality rate independent of age, ABI, and BMI was observed among PAD 
patients with claudication who were able to perform any amount of weekly physical activity 
beyond light intensity in comparison to patients who were sedentary or performed only light-
intensity activities [249].  
Thus, therapeutic approaches that restore or maintain the functional capacity in patients with 
PAD may have a wide-ranging health-promoting effect. Unfortunately, this issue is still 
poorly documented (Figure 2). 
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Figure 2. Inter-relationships between peripheral symptoms, physical disability, cardiovascular risk 
and exercise in patients with peripheral artery disease. Adapted from Hamburg & Creager 
(2017)[45] 
 
 
6. DISEASE MANAGEMENT  
 
The treatment for PAD is closely related to the clinical stage. Recently, two issues derived 
from the recent consensus documents [23] merit emphasis:  
i) The need for the right procedure for the right patient at the right time, choosing lower-cost 
strategies, unless there is evidence justifying a more expensive choice. [23]  
ii) The need for an interdisciplinary team of professionals representing different disciplines 
involved in the evaluation and management of the patient with PAD [23]. 
In the intermediate stage of PAD, of specific interest for the present study, the management 
of patients is mainly based on optimal medical management, exercise and endovascular 
therapy [2]. In particular, the main goals of treatment for patients with IC are i) reduction of 
the risk of major cardiovascular events (MACE; myocardial infarction, stroke, and 
cardiovascular events related to the atherosclerotic diseases [2], ii) improvement of 
claudication symptoms, exercise performance, daily functional abilities and QoL [2,3] and 
iii) prevention of CLI and amputation [2,23].  
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All patients with IC, because of serious health risks, should therefore receive a 
multicomponent therapy based on cardiovascular risk modification and including lifestyle 
coaching and symptomatic treatment [250] (Table 7).  
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Table 7. Management of prevention of cardiovascular events in patients with peripheral artery 
disease. Adapted from Writing Committee Members et al. (2017)[23] and McDermott (2018)[52] 
Intervention Objective Type Product/dose Effect 
Pharmacological 
Prevention of 
cardiovascular 
events 
Antiplatelet 
therapy  
 
• Aspirin   
• Clopidogrel   
 
Uncertain utility  
• Vorapaxar     
 
 
 
• Rivaroxaban   plus 
low-dose aspirin     
Reduced platelet 
activation and platelet 
aggregation  
 
• Lower rates of acute 
limb ischemia and 
revascularization but 
increased bleeding. 
• Lower cardiovascular 
event rates compared to 
aspirin in stable 
atherosclerosis, 
including PAD patients 
Pharmacological 
Prevention of 
cardiovascular 
events 
Hyperlipidemia 
therapy 
Statins  
Pharmacological 
Prevention of 
cardiovascular 
events 
Hypertension 
therapy 
ACE-inhibitors and 
angiotensin receptor 
blockers may have 
advantages for 
patients with PAD 
No evidence of 
superiority of a 
particular class of drugs    
Lifestyle 
Pharmacological 
Prevention of 
cardiovascular 
events 
Pharmacotherapy 
and 
psychological 
support for 
smoking 
cessation 
Advise to quit at 
every clinical visit. 
Pharmacotherapy: 
• varenicline 
• bupropion, 
• nicotine 
replacement therapy 
Reduction/abstention 
from nicotine 
Pharmacological 
Walking 
impairment 
Vasoactive drugs 
Cilostazol  
 
 
 
Pentoxifylline 
• Improvement of 
treadmill walking 
performance (25-40%) 
• No evidence 
Lifestyle 
 
Walking 
impairment 
Exercise therapy 
Supervised 
treadmill exercise  
Home-based 
walking exercise  
Upper and lower 
extremity 
ergometry  
Lower extremity 
resistance training 
Improvement of walking 
performance 
(supervised more 
effective than home-
based and of the other 
forms) 
Abbreviations: PAD: Pefipheral Artery Disease 
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In particular, according to the main guidelines (Figure 3), they should receive a 
comprehensive program of guideline-directed management and therapy, including 
structured exercise and lifestyle modifications, to reduce cardiovascular ischemic events 
and improve the functional status [23] (ACC/AHA Class I recommendations). According 
to the Trans-Atlantic Inter-Society Consensus (TASC), the strategy calls for risk factor 
modification, antiplatelet therapy and structured exercise [3]. In particular, “supervised 
exercise should be made available as part of the initial treatment for all patients with 
peripheral arterial disease” [3,25]. Pharmacotherapy could be prescribed to treat the 
exercise limitation of claudication in selected patients, and revascularization, as the next 
level of decision making, could be considered in the case of a negative response to these 
treatments. When a proximal lesion is suspected, revascularization could be considered 
before extensive medical therapy. According to European Society of Cardiology (ESC) 
guidelines [25], the proven efficacy of endovascular therapy and open surgery for 
improving symptoms, walking ability and QoL in IC is affected by limited durability and 
risks in terms of mortality and morbidity. Therefore, these interventions should be restricted 
to patients who do not respond favorably to exercise therapy (e.g., after a 3-month period), 
or when disabling symptoms substantially alter daily life activities. The proposed 
management of patients are reported (Figure 3).  
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Figure 3. Role of exercise therapy for the management of peripheral artery disease at intermediate stages according to the guidelines of vascular surgeons (A; 
represented by TASC[3]) and of cardiologists (B; represented by ESC[25]) 
 
A            B 
 
Abbreviations: MRA: Magnetic Resonance Angiography; CTA: Computerized Tomography Angiography 
 
 
Terapia de ejercicios para enfermedades crónicas: Discapacidad y resultados clínicos a largo plazo en una cohorte de 
pacientes con enfermedad arterial periférica inscritos en un programa de rehabilitación original 
 
 74 
6.1. Modification of risk factors and medical therapy 
 
Smoking is a major risk factor for the development and progression of PAD; therefore, 
smoking cessation is a vital component of care for patients with PAD who continue to 
smoke [2,23]. It represents the most important lifestyle modification in preventing CLI, 
amputation, and MACE in patients with PAD and it is also associated with better long-term 
outcomes after endovascular intervention [2,251]. Pharmacotherapy group-based programs 
and/or cognitive behavioral therapy could be offered, and the need to stop smoking should 
be discussed during every office visit [2,23].  
Medical therapy to target cardiovascular risk in patients with PAD and IC, which includes 
antiplatelet and statin agents as well as drugs to control diabetes mellitus and hypertension 
[23], reduces cardiovascular morbidity and mortality [8,45]. Unfortunately, medical therapy 
continues to be underutilized by PAD patients [2,8,45,192] compared with patients with 
CAD and other forms of cardiovascular disease [252-255]. According to the 1999 to 2004 
NHANES (National Health and Nutrition Examination Survey) data, among 7,458 subjects 
with PAD, the use of statins, angiotensin-converting enzyme inhibitors and aspirin ranged 
from 25 to 36% [2,8]. Among PAD patients undergoing vascular surgery, only 41% 
achieved guideline-based medication therapy, while the use of recommended therapies was 
associated with a reduced 3-year mortality [45]. 
In relation to antiplatelet therapy, aspirin is recommended in the management of PAD for 
symptomatic patients [23], reducing the risk of major cardiovascular events [254]. 
Uncertainty persists regarding its usefulness for reducing cardiovascular events among 
asymptomatic PAD patients, considering the results of two studies which failed to 
demonstrate a reduction in fatal and nonfatal cardiovascular events or revascularization 
with aspirin monotherapy among low-risk patients with borderline ABI [256-257]. 
Clopidogrel represents a valid alternative for antiplatelet monotherapy among patients with 
PAD who do not tolerate aspirin [2,258-260]. The CAPRIE (Clopidogrel versus Aspirin in 
Patients at Risk of Ischaemic Events) study, in the absence of a clear benefit in the whole 
population compared with aspirin, showed a 23.8% relative risk reduction among the 
subgroup of patients with symptomatic PAD [2,259]. The superiority of ticagrelor compared 
with clopidogrel for the reduction of cardiovascular events was not demonstrated among 
13,500 patients with PAD [261].   
The use of dual-antiplatelet therapy (DAPT) has also been tested in PAD without conclusive 
benefits. A study examining the combination of low-dose aspirin and clopidogrel showed a 
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benefit only in subgroup analyses including patients with symptomatic atherothrombosis 
[262]. Among patients undergoing endovascular intervention, in a population with >50% of 
patients with CLI [263], a significant reduction in MACE among those with DAPT compared 
with those taking aspirin monotherapy was observed in a propensity-matched observational 
study. However, DAPT, usually prescribed for a time period post-intervention, was not 
superior to aspirin monotherapy in the primary endpoint (death, major amputation, index-
graft occlusion, or revascularization) among patients undergoing below-knee surgical bypass 
for the treatment of CLI [264]. Unsatisfactory results in PAD subgroups were also observed 
in trials testing the use of gorapaxar [265]. A study testing the combination of rivaroxaban 
(2.5 mg twice daily) plus aspirin compared with aspirin alone [266] among patients with 
stable atherosclerotic vascular disease showed better cardiovascular outcomes but more 
major bleeding events following combined therapy, with a lowered incidence of major 
adverse limb events and related complications in the subgroup of patients with PAD [267].  
The use of oral anticoagulants to reduce the risk of cardiovascular ischemic events or to favor 
patency after surgical interventions is not recommended [23]. The recent AHA guidelines 
deal with the use of antiplatelet agents and recommended monotherapy in symptomatic 
patients [23]. 
The use of statins is widely recommended in patients with CI and has been shown to reduce 
long-term cardiovascular events regardless of cholesterol starting levels [268]. An 
association of statin use with a reduction in adverse limb outcomes (combined endpoint of 
worsening claudication, new CLI, new revascularization, or amputation) and lower rates of 
ischemic amputation and of amputations have been reported following lower extremity 
revascularization [23,269-271]. High-intensity statin medications are therefore 
recommended by the international guidelines for all patients with PAD on the basis of the 
ACC/AHA guidelines [23,260]. Interestingly, according to some studies, statins may also 
improve the ambulatory capacity in these patients [272-274]. 
In the presence of high systolic blood pressure, all patients with CI   should receive 
antihypertensive treatment to reduce the risk of major cardiovascular complications [23].  
In particular, the use of ACE inhibitors was associated with a significant reduction of 
MACE among patients with PAD [275], with cardiovascular benefits in patients with both 
asymptomatic and symptomatic PAD using ramipril and telmisartan [276-278]. The use of 
ACE inhibitors is therefore considered an appropriate treatment for hypertension in PAD 
[3], with a possible positive impact on exercise capacity among patients with IC [279]. 
Diabetes and hyperhomocysteinemia are also considered by the guidelines. In diabetic 
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patients with PAD [3,23], it is recommended that great attention be paid to the control of 
metabolic compensation to reduce the progression of cardiovascular diseases [280]. 
Conversely, treatment of hyperhomocysteinemia is not supported by the evidence [23].  
Medical therapy to improve claudication is also available. Various drugs have been tested 
for their possible positive effects on the walking capacity of patients with IC [2,3], 
particularly cilostazol and naftidrofuryl [281]. Cilostazol, a type III phosphodiesterase 
inhibitor, improves claudication via unknown mechanisms [282], possibly related both to 
vasodilatory properties mediated by cyclic adenosine monophosphate and its antiplatelet 
activity [283]. The effects of cilostazol on claudication symptoms and QoL have been 
reported in various studies [83,284-287]. In addition, its effects in terms of reduced intimal 
hyperplasia [288], suggest a possible use after invasive procedures of revascularization 
[289]. This drug, which is safe for long-term administration has low adherence due to 
adverse effects (headache, palpitations, and diarrhea) [290], and it is also contraindicated in 
patients with a history of heart failure [2]. Naftidrofuryl, a 5-HT2 antagonist approved in 
Europe, improves muscle metabolism and reduces erythrocyte and platelet aggregation [3]. 
It was found to be effective for claudication [291], with a 26% increase in pain-free walking 
compared with placebo determined in a pooled analysis [292]. Pentoxifylline, which has 
been reported to improve red cell and white cell deformability with lower blood viscosity 
[3], was not effective for the treatment of claudication in various studies and meta-analyses 
[3,293-295] (Table 7).   
 
6.2. Invasive treatment  
 
Endovascular revascularization plays a key role in the management of patients with PAD [2]. 
In general, the optimal revascularization procedure varies according to the severity and 
characteristics (site and diffusion) of PAD disease, which are defined by well-established 
classification schemes. Besides the previously described functional assessment (Fontaine or 
Rutherford classification), the anatomic lesion classification (Trans-Atlantic Inter-Society 
Consensus [3] classifies the aorto-iliac and the femoro-popliteal lesions into four groups (A, 
B, C, D), associating them with a specific treatment (Figure 4). 
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Figure 4. Atherosclerotic lesions classifications according to TASC[3] 
Abbreviations: CIA: Common Iliac Artery; EIA: External Iliac Artery; CFA: Common Femoral Artery; AAA: Abdominal Aortic Aneurysm; SFA: Superficial Femoral Artery 
 Tasc A Tasc B Tasc C Tasc D 
Aorto-iliac Unilateral or bilateral 
stenosis of CIA 
Unilateral or bilateral single 
short (< 3cm) stenosis of 
EIA 
 
 
 
Short (< 3cm) stenosis of infrarenal aorta 
Unilateral CIA occlusion 
Single or multiple stenoses totaling 3-
10cm involving the EIA, not extending 
into CFA 
Unilateral EIA occlusion not involving 
the origins of internal iliac or CFA 
 
Bilateral CIA occlusions 
Bilateral EIA stenoses 3-10cm long, not 
extending into CFA 
Unilateral EIA stenosis extending into 
the CFA 
Unilateral EIA occlusion that involves 
the origins of internal iliac and/or CFA 
Heavily calcified unilateral EIA 
occlusion with or without involvement of 
origins of internal iliac and/or CFA 
 
Infrarenal aorto-iliac occlusion 
Diffuse disease involving the aorta and both 
iliac arteries 
Diffuse multiple stenoses involving the 
unilateral CIA, EIA and CFA 
Unilateral occlusions of both CIA and EIA 
Bilateral occlusion of EIA 
Iliac stenoses in patients with AAA not 
amenable to endograft placement 
 
Femoral-
popliteal 
Single stenosis < 10cm 
length 
Single occlusion < 5cm 
length 
 
Multiple lesions (stenoses or occlusions) 
each < 5cm 
Single stenosis or occlusion < 15cm, not 
involving infrageniculate popliteal artery 
Heavily calcified occlusion <5cm 
Single popliteal stenosis 
 
Multiple stenoses or occlusions totaling 
>15cm, with or without heavy 
calcification 
Recurrent stenoses or occlusions after 
failing treatment 
 
Chronic total occlusion of CFA or SFA 
(>20cm involving the popliteal artery) 
Chronic total occlusion of popliteal artery 
and proximal trifurcation vessels 
 
 
Infra-
popliteal 
Single focal stenosis, < 5cm 
length, in the target tibial 
artery, with occlusion or 
stenosis of similar or worse 
severity in the other tibial 
arteries 
Multiple stenoses, each < 5cm length, or 
total length < 10cm, or single occlusion 
<3cm in length, in the target tibial artery 
with occlusion or stenosis of similar or 
worse severity in the other tibial arteries 
Multiple stenoses in the target tibial 
artery and/or single occlusion with total 
lesion length >10cm with occlusion or 
stenosis of similar or worse severity in 
the other tibial arteries 
Multiple occlusions involving the target 
tibial artery with total lesion length > 10cm, 
or dense lesion calcification or 
nonvisualization of collaterals; the other 
tibial arteries occluded or with dense 
calcification. 
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Endovascular therapy is an optimal treatment for A type lesions and good treatment for B 
type lesions; C lesions produce better long-term results after surgical revascularization. 
However, most PAD patients requiring intervention generally show multiple lesions, at one 
or more levels, and therefore, these schemes are limited by the need to individually consider 
the type of lesion. In some cases, the study of the angiosome, an anatomic unit of tissue 
(consisting of skin, subcutaneous tissue, fascia, muscle, and bone) that is fed by a source 
artery and drained by specific veins, offers further information about optimal 
revascularization strategies for limb salvage [2, 296]. However, for the majority of PAD 
patients requiring revascularization, the “endovascular first” approach is advised by the 
consensus documents [2,3,23]. In particular, endovascular treatment should be performed for 
hemodynamically significant lesions targeting selected stenosis with a reasonable likelihood 
of limiting perfusion to the distal limb [23]. Its role in IC is related to an improvement in 
claudication symptoms rather than the limb salvage, considering that only a few patients with 
IC will progress to CLI [23,176,297-299], and it should be considered in the presence of 
persistent lifestyle-limiting claudication after pharmacological and exercise therapy 
[2,3,23,87,300-303] defined by the patient [23]. However, the feasibility of the treatment is 
related to the presence of comorbidities, the favorable risk–benefit ratio, and the preferences 
of the patients. Clear information about expected risks, benefits and durability of the 
revascularization procedures (Figure 5) is necessary to support patient decisions [23].  
Figure 5. Five-year percentage patency estimates according to TASC[3] 
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If revascularization in IC is useful, feasible and accepted, it needs to be personalized to 
improve outcomes on the basis of the available endovascular techniques (angioplasty, 
stents, and atherectomy and covered stents, drug-eluting stents, cutting balloons, and drug-
coated balloons) for the lesions (e.g., anatomic location, lesion length, degree of 
calcification), as well as the experience of the operator [23].  
The surgical option, which is effective for QoL and walking capacity in IC, may offer better 
functional and patency outcomes compared with endovascular treatments, but with a greater 
risk of adverse perioperative events [23]. Therefore, in these patients the more invasive 
option is usually performed in the case of inadequate benefit from nonsurgical therapy, of 
the arterial anatomy, which offers a durable result, and in the presence of an acceptable risk 
of perioperative adverse events in relation to the symptom severity and comorbidities. In 
particular, femoral-popliteal bypass is one of the most common surgical procedures among 
patients with claudication, as the superficial femoral is a typical anatomic site of stenosis or 
occlusion. For lesions at the popliteal artery, the site of anastomosis (above versus below the 
knee) [23] and the type of intervention, e.g., autogenous vein versus prosthetic grafts, 
positively influence the outcomes of the intervention [304-305]. 
 
6.3. Exercise therapy   
 
Exercise therapy has a pivotal role in this management of patients with IC, representing the 
first intervention that is potentially able to improve the status of the patients and to condition 
future actions [3] with well-demonstrated benefits [1,23,25,250,260]. Since 1898, exercise, 
particularly walking, has been proposed as a therapy for IC [294]. In 2001, the proven clinical 
efficacy of exercise in the treatment of claudication resulted in the creation of a Current 
Procedural Terminology Code (CPT 93668) for PAD rehabilitation [45].  
As previously reported, patients with PAD present with a complex array of symptoms and 
limitations in their daily lives [306-307], which accelerates the functional decline leading to 
physical disability [45,100,202]. The goal, therefore, is to improve the exercise performance 
of patients with symptomatic PAD to prevent or lessen their physical disability and improve 
QoL and functional status [2]. A well-established benefit has been reported after a typical 12-
week exercise training program [2,208-309]. In addition, considering that in PAD patients 
reduced physical activity in daily life [310-311] and low exercise capacity are associated with 
increased mortality and risk of cardiovascular events [138,189,197,199,244], exercise 
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training when included in a comprehensive prevention strategy can reverse this condition and 
alter the clinical trajectory of these patients, even in the absence of claudication [45,247].  
The functional benefits of exercise in PAD are likely attributable to several possible 
beneficial adaptations (Figure 6), to an opposition to the above-discussed 
pathophysiologic and maladaptive processes [45] and in general to the atherosclerotic 
disease.   
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Figure 6. Physiopathological process, evolution of disease and effect of exercise interventions in 
patients with peripheral artery disease. 
 
Abbreviations: ROS: Reactive oxygen species; NO: nitric oxyde 
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The factor that contributes the most remains unclear [1]; however, it is certain that different 
factors play a role, such as improved vascular angiogenesis, reduced endothelial and 
mitochondrial dysfunction, reduced inflammation and favorable metabolic adaptations 
within skeletal muscle [1,250,312-316]. Reduced levels of inflammatory markers [317], 
improved endothelium-dependent vasodilation [318], increased capillary density of the 
gastrocnemius muscle [319], and altered skeletal muscle metabolism through an increase in 
oxidative enzymes have been reported following supervised exercise [320]. Exercise training 
may also upregulate antioxidant enzymes and enhance nitric oxide release [125,237-
238,241,321-323] with induced angiogenesis and vascular regeneration, which are also 
mediated by endothelial progenitor cells (EPCs) [125,237-238,322-324]. These cells, as 
predictors of cardiovascular events [235,236], were found to be increased following acute 
and chronic exercise in healthy subjects and in patients with cardiovascular diseases, end-
stage renal disease (ESRD) and PAD [241,325-328]. Exercise training by evoking local 
tissue hypoxia and changes in shear stress with the local induction of growth factors, 
cytokines and endothelial nitric oxide synthase may induce vascular structural remodeling 
[125,237-238,241,321-323]. An augmented peripheral arterial supply [329-332] and gains in 
collateral blood flow through collateral enlargement have been observed in animal models of 
arterial insufficiency following exercise training [329,333-335]. Unfortunately, in PAD 
patients, exercise programs fail to produce clinically relevant gains in peripheral blood flow 
when a minimal or absent ABI change is reported [45,181]. A meta-analysis of 7 exercise 
training studies demonstrated no change in the resting ABI, as confirmed by a recent 
Cochrane report [99,169]. The quality and duration of the training stimulus have been 
hypothesized to explain the difference in response in terms of an increased blood supply 
between the animal and human studies [314]. However, few studies based on new training 
programs aimed at maximizing the induction of aerobic adaptations have shown significant 
ABI changes [168,336-340] and related angiogenic adaptations [242,340-341]. It is also well-
known that exercise therapy, favoring better control or a reduction of cardiovascular risk 
factors such as diabetes mellitus, hypertension, and dyslipidemia [1-3,342], is an important 
part of secondary prevention therapies for patients with coronary artery disease [1,343-344]. 
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6.3.1. The exercise programs  
To better address the topic, it is useful to refer to the recent definition of the AHA guidelines 
related to the key terms (Tables 8) and the modalities of vascular rehabilitation in PAD 
patients (Table 9) [23]. 
Table 8. Key-terms in peripheral artery disease (intermediate stage). Adapted from Olin et al. 
(2016)[2] and Writing Committee Members et al. (2016)[23] 
Claudication Fatigue, discomfort, cramping, or pain of vascular origin in the 
muscles of the lower extremities that is consistently induced by 
exercise and consistently relieved by rest (within 10-min). 
Functional status  Patient’s ability to perform normal daily activities required to meet 
basic needs, fulfill usual roles, and maintain health and well-being.  
Walking ability is a component of functional status. 
Structured exercise  program Planned program that provides individualized recommendations for 
type, frequency, intensity, and duration of exercise. 
Program provides recommendations for exercise progression to 
assure that the body is consistently challenged to increase exercise 
intensity and levels as functional status improves over time. 
There are 2 types of structured exercise program for patients with 
PAD: 
1. Supervised exercise program 
2. Structured community- or home-based exercise program 
Supervised exercise program The program takes place in a hospital or outpatient facility in which 
intermittent walking exercise is used 
  
Structured community- or home-
based exercise program 
The program that takes place in the personal setting of the patient 
rather than in a clinical setting  
Interdisciplinary care team  
 
 
 
A team of professionals representing different disciplines to assist in 
the evaluation and management of the patient with PAD.  
The team members may include: 
Vascular medical and surgical specialists (i.e., vascular medicine, 
vascular surgery, interventional radiology, interventional 
cardiology) 
Nurses 
Orthopedic surgeons and podiatrists 
Endocrinologists 
Internal medicine specialists 
Infectious disease specialists 
Radiology and vascular imaging specialists 
Physical medicine and rehabilitation clinicians 
Orthotics and prosthetics specialists 
Social workers 
Exercise physiologists 
Physical and occupational therapists 
Nutritionists/dieticians 
PAD -related events 
                   Limbs 
Worsening claudication,   
Critical limb ischemia (chronic or ≥2 wk) ischemic rest pain, non-
healing wound/ulcers, or gangrene in 1 or both legs attributable to 
objectively proven arterial occlusive disease 
Hospitalization: new lower extremity revascularization, or new 
ischemic amputation 
PAD -related events 
                   Cardiovascular system 
Hospitalization: Acute coronary syndrome (acute MI, unstable 
angina), stroke; cardiovascular death 
PAD -related events 
                   Specialists involved 
Individuals who are skilled in endovascular and/or surgical 
revascularization, wound healing therapies and foot surgery, and 
medical evaluation and care. 
Abbreviations: PAD: peripheral artery disease; MI: myocardial infarction; wk: week 
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Table 9. Comparison of supervised exercise program and community- or home-based exercise 
program in peripheral artery disease. Adapted from Olin et al. (2016)[2] and Writing Committee 
Members et al. (2016)[23] 
Type 
Supervised exercise program 
(COR I, LOE A) 
 
Structured community- or home-
based exercise program 
(COR IIa, LOE A) 
Setting  Hospital or outpatient facility Program takes place in the personal 
setting of the patient rather than in a 
clinical setting 
Organization:   
 
Standalone or within a cardiac 
rehabilitation program. 
 
Directly supervised by qualified 
healthcare provider(s) 
Program is self-directed with guidance 
of healthcare providers. 
Patient counseling ensures 
understanding of how to begin and 
maintain the program and how to 
progress the training load (by increasing 
distance or speed) 
Training/Modality Intermittent walking exercise Intermittent walking exercise 
(generally)  
Program may incorporate behavioral 
change techniques, such as health 
coaching or use of activity monitors 
Training/Frequency 
 
Sessions performed 3 times/week 
supervised 
 
Training/Duration  
 
A minimum of 12 weeks 
 
Healthcare providers prescribe an 
exercise regimen similar to that of a 
supervised program 
Training/ Session Performed for a minimum of 30–45 
min/session intermittent bouts of 
supervised walking   
Warm-up and cool-down periods  
Healthcare providers prescribe an 
exercise regimen similar to that of a 
supervised program 
Exercise 
prescription 
 
Intensity  
 
 
 
Claudication 
Intensity 
 
 
Work-to-rest ratio  
 
 
 
 
Progression  
 
 
 
 
 
 
 
Maintenance 
 
 
 
40%–60% maximal workload based on 
baseline treadmill test or workload that 
brings on claudication within 3–5 min 
during a 6-MWT 
Moderate to moderate/severe 
claudication as tolerated 
 
3-2:1   
Walking duration should be within 5–10 
min to reach moderate to moderately 
severe claudication followed by rest 
until pain has dissipated (2–5 min) 
 
Every 1–2 wk: increase duration of 
training session to achieve 50 min 
As individuals can walk beyond 10 min 
without reaching prescribed 
claudication level, manipulate grade or 
speed of exercise prescription to keep 
the walking bouts within 5–10 min 
 
Lifelong, at least 2 times per week 
 
 
 
Healthcare providers prescribe an 
exercise regimen similar to that of a 
supervised program. 
 
Abbreviations: COR: Class of Recommendation; LOE: Level of Evidence; 6-MWT: Six-minute walk test 
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The first main classification is between unstructured and structured exercise programs.  
Unstructured programs are those in which exercise therapy prescription is based on walking 
advice [WA], consisting mostly of "go home and walk" advice, from the physician (e.g., 
general practitioner, vascular surgeon) [1]. This unsupervised approach based on a general 
recommendation to walk more is usually considered ineffective [23,345]. Alternatively, the 
physician may provide a comprehensive exercise prescription to offer a home exercise 
program [2,314,346] that is not based on a one-time recommendation but a continued 
discussion in an attempt to change the patient’s behavior [2].  
In contrast, structured exercise programs are planned programs that provide individualized 
recommendations concerning the type, frequency, intensity, and duration of exercise. The 
progression of the training load causes adaptations in the body that improve the functional 
status over time [23]. Two types of structured exercise program are now recognized for 
patients with PAD: supervised exercise programs and structured community- or home-based 
exercise programs [23] (table 9).  
  
6.3.1.1. Supervised exercise programs 
 
Supervised exercise programs, carried out in a hospital or outpatient facility, can be 
autonomous or part of a cardiac rehabilitation program. The treatment modality involves 
intermittent bouts of treadmill walking to moderate-to-maximum claudication, alternating 
with periods of rest. Warm-up and cool-down periods precede and follow each session of 
walking, which are directly supervised by qualified healthcare providers. Training is 
performed for a minimum of 30 to 45 min per session, in sessions performed at least 3 
times/week for a minimum of 12 weeks [23,78,87,134,181,301,308,347-351].  
Structured community- or home-based exercise programs, which have been proposed more 
recently, take place in the personal setting of the patient rather than in a clinical setting 
[23,349,352-354]. These programs, which may incorporate behavioral change techniques 
(health coaching and/or the use of activity monitors) are self-directed with the guidance of 
healthcare providers, who prescribe a structured exercise program comparable to that of a 
supervised program. The patient receives detailed information on how to begin the program, 
how to maintain the program or how to increase the training load (e.g., by increasing the 
walking distance or speed) throughout the program (table 9).   
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Supervised exercise programs have been recommended as the first-line therapy for the 
treatment of IC [3,23,181,314], after which RCTs have consistently demonstrated their 
capacity to significantly improve PFWD and MWD, as assessed by graded treadmill testing 
in people with PAD [1,52,77,169,349,355-356] both with and without classic symptoms of 
claudication [96,98]. In 1995, a meta-analysis of 21 studies (3 were RCTs) [355] reported an 
improved treadmill MWD by 122% and PFWD by 179% following SET based on treadmill 
walking [52]. The most effective programs included at least 3 supervised sessions per week 
of exercise performed walking to maximal or near-maximal ischemic pain for at least 30 min 
per session, for a 6-month duration or longer [52,96,98,355]. A rigorous systematic review 
including only controlled clinical trials (22 studies with more than 1200 participants) 
compared SET to usual care in the treatment of claudication [357]. Exercise induced 
clinically relevant increases in walking time (5 minutes) and walking distance (>100 meters) 
[357], with a magnitude of functional benefit derived from training exceeding that observed 
in drug therapy trials with both pentoxifylline and cilostazol [314,358]. A meta-analysis 
performed by Fakhry et al. in 2012 [73], including the results of 25 RCTs of treadmill-based 
SET in 1054 patients with PAD and IC, reported an improvement of treadmill MWD between 
50% and 99% for 15 studies and >100% for 5 of them [52,359]. In addition, measures of 
functional status and health-related QoL were improved following treadmill-based SET 
programs [77,87,134,301,308,317,360-361]. Another meta-analysis by Parmenter and 
colleagues showed a significant mean improvement in COD and PWD after treadmill-based 
SET in the studies with 12-week or longer interventions [349]. 
The Cochrane reviews have progressively compared the effects of SET with nonsupervised 
exercise therapy [1,361]. A Cochrane review in 2006 [361] including 8 small randomized 
trials (a total of 319 participants) concluded that SET was superior to nonsupervised exercise 
with a 150 m greater improvement in walking time [314,361]. Consequently, the ACC-AHA 
2005 Practice Guidelines for the Management of Patients with Peripheral Arterial Disease 
provided a Class I recommendation for SET and only a Class IIb recommendation for 
unsupervised training. In addition to the health benefits of a daily increase in physical 
activity, limited supporting symptom-based evidence has been provided for programs simply 
advising patients to walk more independently [314,362] due to lower intensity and poor 
adherence in comparison to supervised treadmill exercise. 
As reported, SET training sessions are based on bouts of treadmill walking to moderate-to-
maximum claudication, alternating with periods of rest. Recently, the components of a SET 
program (intensity, amount of exercise per session, claudication level, progression of volume, 
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work-to-rest ratio, frequency of sessions, and program duration) have been reviewed [77]. In 
relation to intensity, the percentage of the measured maximal workload or peak oxygen 
consumption (VO2) attained during a standardized treadmill test was considered. This 
parameter was related to an improvement in peak Vo2 rather than in walking distance [363]. 
The claudication severity during walking, was mainly considered. Most studies have been 
performed at a moderate or near-maximal level of claudication [23,73,169,355-356,364]; 
however, no difference was found when exercising to a mild claudication level in comparison 
to severe claudication [365]. 
The optimal duration of exercise per session has been poorly studied, with sessions lasting 
>30 to 60 minutes being more beneficial [355], or 30-45 minutes [73,349,356]. The 
progression of increasing volume of exercise, which includes both duration and workload of 
the task, has not also been adequately investigated. A gradual progression of exercise should 
occur throughout the program to favor continued adaptation to the training stimulus on the 
basis of each individual patient. Similarly, the optimal work-to-rest ratio has not been studied 
due to the mentioned difficulty in standardizing rest periods, when the time of pain 
dissipation differs among individuals [366]. The Frequency of the SET program, according 
to meta-analyses, should be at least 3 times per week [23], but the optimal frequency of 
exercise training to achieve the best outcomes in terms of walking distance has not been 
specifically studied in RCTs. Finally, the program duration of SET should range from 12 
weeks to 6 months [23,73,169,355-356,364], with a largest effect size in treadmill walking 
performance at 3 months [73,169,349,364,367]. A more gradual response to SET has been 
observed for the 6MWT distance, which peaks after 6 months of exercise training [96].  
According to the AHA guidelines [23], SET programs are associated with effectiveness 
[23,78,134,169,181,308,349-351,353], persistent benefit [87,301,347], favorable risk–
benefit ratio and safety [23]. Reported absolute contraindications are related to exercise-
limiting cardiovascular disease, amputation or wheelchair confinement, as well as other 
major comorbidities that would preclude exercise [99,347-348,368-371].  
However, a certain variability in the response has been underlined. One of these factors is the 
magnitude of improvement of the treadmill distance observed in RCTs. The changes of COD 
following 12-week interventions range from 92 to 243 m among the studies and from 191 to 
402 m for PWD [98,112,115,123,165,308-309,348-349,367,368,372-376]. These changes in 
PWD are greater than 50% in 71% of trials analyzed and higher than 100% improvement in 
21% of trials [73,77]. However, a factor of great interest is also the “non-response” to 
interventions. Among 24 walking-based trials (both treadmill-based and non-treadmill 
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walking) included in a meta-analysis for PWT [73] and 20 trials included in the meta-analysis 
for COT, 37.5% of them (9 and 7, respectively) showed no benefit of SET compared with 
the control. Factors such as age, 6MWT performance, ABI value, sex, black race, presence 
versus absence of diabetes mellitus [354] or presence versus absence of exertional leg 
symptoms or claudication symptoms [98] were not recognized as useful to identify 
nonresponders to walking exercise interventions. Interestingly, less improvement after 
treadmill-based SET has been observed for patients with more severe IC [77]. Controversial 
results have been reported for gender, with significantly greater PWT for men than women 
in a randomized trial of SET, with no difference in response in the GOALS (Group Oriented 
Arterial Leg Study) trial [354], or with lower rates of improvements in COT for women in 
the presence of diabetes [377]. The wide timespan (more than 20 years) of the studies, the 
variability of the patients included and the  different exercise training protocols used have 
been considered to explain the differences [73,77]. However greater benefits were observed 
between 12 to 26 weeks of duration compared with shorter or longer programs [73,77]. 
  
6.3.1.2. Home-based programs 
 
Although SET programs have been shown to be more effective in increasing MWD and 
PFWD or time compared with nonsupervised exercise programs, [ 1 , 378 ]  the structural 
weaknesses of the SET programs have emerged over time, leading to their underutilization 
[1]. In 2012, an international survey reported that SET programs were poorly 
available to vascular surgeons and differently implemented [378]. The policy change in 
the USA regarding coverage for supervised treadmill exercise under determined conditions 
is expected to increase access to supervised exercise for large numbers of patients with PAD 
[52]. However, the problem of participation was confirmed by a systematic review analyzing 
the rate of recruitment of PAD for RCTs for SET programs, which showed that 69% of 
eligible participants refused participation, partly because of the SET program requirements 
[379]. In general, issues of reimbursement, awareness, and motivation for these programs and 
problems related to patient transportation and elig ibility affect SET programs, 
as well long-term adherence to exercise with a limited impact on patient’s lifestyle 
[181,250,315,379-381].   
The proposed structured home-based exercise interventions (SH-BEx) may provide an 
effective alternative to hospital-based SET programs [382-383]. SH-BEx overcome or reduce 
some barriers to exercise, such as the availability of facilities [1,378], funding for hospital-based 
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SET programs [382-383], transportation time and costs for individual patients and families 
[52]. They also improve overground walking, which is necessary in daily life [68,74]. Since 
2011, three RCTs have demonstrated significant benefit from structured SH-BEx in patients 
with PAD [77]. In the GOALS trial, a group-mediated cognitive behavioral intervention 
achieved a greater increase in 6MWT performance in PWT and in COT compared with the 
control group [354]. A study showed that 6MWT improved more significantly in the home-
based exercise group compared with the SET group [99]. In contrast, a trial showed no 
differences in PWT or COT (primary outcome) between a home-based intervention 
(counseling session at baseline, 1 walking session per week with an instructor at an exercise 
center and 3 days of walking at home for up to 50 minutes of exercise per session) and the 
control group [352]. Finally, a recent randomized trial of structured HB-Ex that tested the 
ability of telephone calls by a coach combined with a wearable activity monitor showed no 
improvement in the 6MWT at the 9-month follow-up [118].   
However, home-based exercise training is considered reasonable for patients with PAD [23] 
and is recommended with a Class IIa Level of Evidence A by AHA/ACC clinical practice 
guidelines for PAD. In these programs, patients with PAD have generally been advised to 
walk for exercise 3 to 5 times per week at a self-selected or to maximal ischemic leg pain, 
starting with 10 minutes of walking per session and increasing the duration by ≈5 minutes 
per session each week up to a duration of 45 to 50 minutes per session (excluding rest periods) 
[97,99,368].   
The methodology of these programs has been favored by education and behavioral 
interventions [2,352] and use of observation components [ 99, 368,378 ] .  Exercise 
logbooks, pedometers or new technological devices monitor the duration and intensity of 
home exercise sessions, facilitate self-monitoring [97,99,368], enable periodical coaches or 
clinicians and favor specific walking advice. The obtained results to date are considered 
encouraging [2]. Among these programs, an original model of the SH-BEx program based 
on a specific testing session in the hospital and on a precise exercise prescription to be 
executed at home has been reported in different studies since 2004 by Manfredini and 
colleagues and proposed in 2008 [336-337]. A section will be dedicated to the rationale and 
results of this intervention model. 
After the development of home-based (HB) programs, various reviews have evaluated the 
effects of different conservative treatment options in IC, including a version of the Cochrane 
comparing SET with HB-Ex and with WA [1,73,169,300,361,364,384-387]. The first 
systematic review on the effectiveness of H-BEx programs included 12 studies. In three 
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studies, SET was superior to H-BEx in improving functional capacity or equivalent in 
improving QoL, while H-BEx compared with WA and baseline measurements significantly 
improved most of the functional capacity and QoL markers [378]. Three randomized trials 
showed that walking exercise in a home setting significantly improved walking ability and 
the 6MWT more than a treadmill-based SET program, compared to the control group (by 45 
to 54 m vs 15−35 m). [96-99,368]. A recent Cochrane review comparing the treatments [1] 
included 21 studies involving a total of 1400 participants (SET= 635, H-BEx= 320, 
WA=445). SET showed an important benefit for treadmill-measured walking distance 
(MWD and PFWD) compared with H-BEx and WA, respectively. In this case no clear 
evidence of a difference between H-BEx and WA was observed. However, no clear 
differences in QoL parameters or in self-reported functional impairment between SET and 
H-BEx were observed [1]. 
The effects of SET versus revascularization, another therapeutic option for patients with IC, 
have also been compared in different studies [77]. Comparison of SET versus 
Revascularization versus SET Plus Revascularization in patients with above-the-knee 
occlusive disease and IC showed similar improvements among the three groups alone, with 
the best results observed for the group combining the treatments [388]. Similar results [389] 
were obtained in patients with femoro-popliteal disease and IC when comparing the effects 
of angioplasty, SET, and angioplasty plus SET with improved outcomes (PWD and QoL) 
[389-390]. The comparison of SET versus Revascularization showed a significant change at 
3 months following angioplasty [391], which remained stable up to 15 months, while 
improvements of PWD in the SET group were observed up to 15 months. Conversely, better 
results in terms of functional improvement were reported following open surgical or 
endovascular procedures at the 1-year follow up compared to the SET or control group [392]. 
A significantly lower rate of patients with IC was reported in patients undergoing primary 
endovascular revascularization versus those performing SET, with a loss of this difference at 
12 months, at which time functional data and QoL scores improved in both groups [393]. 
Comparison between SET versus SET Plus Revascularization in a trial including femoro-
popliteal patients showed significantly higher COD and PWD (the primary outcomes) at the 
24-month follow-up in the group combining the treatments [394]. Similar, but not statistically 
significant, the results were acquired in the aortoiliac trial [394]. Again, in the ERASE 
(Endovascular Revascularization and Supervised Exercise) trial, the primary end point, or 
the difference in PWD on the treadmill at 12 months, and the secondary outcomes (COD, 
VascuQoL score, and SF-36 physical functioning score) were significantly greater in the 
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group receiving combination therapy than in the SET alone group [395], which was also 
highly effective per se in walking ability and QoL [314].  
 
Comparison of SET versus Revascularization versus Optimal Medical Therapy in patients 
with aortoiliac PAD (CLEVER; Claudication: Exercise versus Endoluminal 
Revascularization) [87] at the 6-month follow-up showed the largest improvement in PWT 
(the primary end point) in SET, followed by stenting and finally optimal medical care. 
Health-related QoL, a secondary end point, was significantly improved in the SET and 
stenting groups [87].  
A Cochrane review [396] of 10 RCTs comparing endovascular revascularization (± 
conservative therapy consisting of supervised exercise or pharmacotherapy) versus no 
therapy (except advice to exercise) or versus conservative therapy (i.e., supervised exercise 
or pharmacotherapy) for IC, confirmed the synergetic effect of endovascular 
revascularization combined with SET or pharmacotherapy with cilostazol, without 
significant changes in the functional performance or QoL of endovascular revascularization 
alone compared with SET alone [396].  
Recently, a pilot randomized study compared the SH-BEx Test in-Train out (Ti-To) walking 
program [336] with hybrid revascularization procedures in elderly patients with PAD at 
Fontaine’s second stage with severe IC over a 4-month period [168]. The study showed a 
lack of significant between-group differences in the physical component summary score of 
the SF-36 questionnaire (primary outcome). Both treatments significantly increased this 
parameter, as well as some secondary outcomes, including treadmill measures (ICD, ACD) 
and pain-free walking distance in the 6MWT. As expected, ABI and 6MWT were 
significantly improved in the revascularization group.   
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6.3.1.3. Alternative modes of exercise 
 
For patients with IC, however, other modes of exercise have been proposed. Some authors 
have evaluated the efficacy of lower-extremity cycling to improve claudication in patients 
with PAD [370,397-398]. A study in patients with symptomatic PAD performing 6 weeks of 
treadmill walking, or leg cycling (2 minutes of rest, for a total of 20 minutes of exercise per 
session), or control showed a reduced improvement of PWD for the leg-cycling group, in 
which a group of patients showed a positive response to this type of training. In two other 
studies [370,398], a significant increase was observed in the distance covered in a shuttle test 
in the leg-cycling group compared with the control participants. The aerobic arm training 
was also studied. Twelve weeks of 3 times per week supervised treadmill training or arm 
cycling alone or in combination versus usual care in patients with claudication showed an 
improvement in COD and PWD in the arm-cycling group versus controls, demonstrating that 
walking ability in people with PAD could be significantly improved by upper-extremity 
aerobic exercise [348,399].  
The effects of Lower extremity Resistance Training versus treadmill walking performance in 
patients with IC in studies with insufficient statistical power showed non-univocal results 
[52,98,134,400] with lower [309] or comparable effects [98,401]. High-intensity resistance 
training for seven different muscle groups was superior to low-intensity resistance training 
in improving walking distance in individuals with PAD [402]. 
 
6.3.1.4. Alternative modes of walking 
 
- Nordic walking: Nordic walking or Nordic pole walking, a core-focused walking 
technique assisted by special poles, reduces the load on the legs during walking by 
involving the muscles of the arms and trunk [403]. A recent systematic review [403] 
analyzing data from five trials (three comparing supervised Nordic walking programs 
with supervised standard walking) demonstrated no advantage of Nordic walking 
programs over control programs. 
- Pain-free treadmill walking: Supervised pain-free treadmill training was tested in 
randomized trials, which was based on walking until the onset of claudication [404-
407]. Three trials showed a significantly higher functional improvement compared 
with the controls [404-406] or did not differ from that observed in a group walking to 
moderate claudication pain [407].  
Terapia de ejercicios para enfermedades crónicas: Discapacidad y resultados clínicos a largo plazo en una cohorte de 
pacientes con enfermedad arterial periférica inscritos en un programa de rehabilitación original 
 
 94 
6.3.2. The Test in-train out Pain-Free walking program  
 
An early prototype of the SH-BEx program based on an alternative model of walking for 
rehabilitation was developed and tested 15 years ago at the Vascular Diseases Center of the 
University of Ferrara, through the Vascular Rehabilitation Program [408]. The Ti-To model 
(Table 10) was conceived and proposed when structured home-based exercise programs were 
not yet available. However, at that time, it was already clear that a third route between the 
structured programs under continuous supervision and the unsupervised unstructured 
programs based on simple advice and recommendations was reasonable.  
This patient-centered model provides the complete execution of the home exercise and circa-
monthly check ups in the structure to determine the degree of disability and to receive the 
exercise prescription or the update regarding the training program. The program has two 
original aspects to be considered: the physiological approach to patient training and the 
organizational issues.     
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Table 10. Comparison of traditional exercise programs with the Test in-Train out (Ti-To) program 
in peripheral artery disease. 
Type 
Supervised exercise program 
(COR I, LOE A) 
 
Structured community- or 
home-based exercise 
program 
(COR IIa, LOE A) 
Structured home-based exercise 
program Ti-To 
 
Setting  Hospital or outpatient facility 
Program takes place in the 
personal setting of the patient 
rather than in a clinical 
setting 
Prescription: in a hospital or 
outpatient facility 
Execution: home 
Organization:   
 
Standalone or within a cardiac 
rehabilitation program. 
 
Directly supervised by qualified 
healthcare provider(s) 
Program is self-directed with 
guidance of healthcare 
providers. 
Patient counseling ensures 
understanding of how to 
begin and maintain the 
program and how to progress 
the training load (by 
increasing distance or speed) 
Program is prescribed by doctors and 
exercise physiologists after a battery 
of hemodynamic and functional tests  
The exercise is performed at home 
The patient is periodically re- tested 
to update the program prescription 
and to verify the adherence   
Training/Modality Intermittent walking exercise 
Intermittent walking exercise 
(generally)  
Program may incorporate 
behavioral change 
techniques, such as health 
coaching or use of activity 
monitors 
Intermittent walking exercise at 
prescribed speed maintained walking 
in rhythm with a metronome  
The exercise is performed inside 
home, in a corridor 
Log-book for recording exercise   
Training/Frequency 
 
Sessions performed 3 
times/week supervised 
 5-6 days/week 
Training/Duration  
 
A minimum of 12 weeks 
 
Healthcare providers 
prescribe an exercise regimen 
similar to that of a supervised 
program 
16-32 weeks 
Training/ Session 
Performed for a minimum of 
30–45 min/session intermittent 
bouts of supervised walking   
Warm-up and cool-down 
periods  
Healthcare providers 
prescribe an exercise regimen 
similar to that of a supervised 
program 
Two daily 10-minute walking 
sessions 
Exercise 
prescription 
 
Intensity  
 
 
 
 
Claudication 
Intensity 
 
 
Work-to-rest ratio  
 
 
 
 
 
 
 
Progression  
 
 
 
 
 
 
 
Maintenance 
 
 
40%–60% maximal workload 
based on baseline treadmill test 
or workload that brings on 
claudication within 3–5 min 
during a 6-MWT 
Moderate to moderate/severe 
claudication as tolerated 
 
3-2:1   
Walking duration should be 
within 5–10 min to reach 
moderate to moderately severe 
claudication followed by rest 
until pain has dissipated (2–5 
min) 
 
Every 1–2 wk: increase 
duration of training session to 
achieve 50 min 
As individuals can walk beyond 
10 min without reaching 
prescribed claudication level, 
manipulate grade or speed of 
exercise prescription to keep the 
walking bouts within 5–10 min 
 
Lifelong, at least 2 times per 
week 
 
 
Healthcare providers 
prescribe an exercise regimen 
similar to that of a supervised 
program. 
 
 
 
From slow speed (60 steps/min) to 
habitual speed (96-110 steps/min) for 
1-minute, followed by 1-min of rest 
  
Pain-free 
 
 
1:1  
(sitting in the rest period) 
 
For the first phase (1-min work / 1-
min rest) then 2:1 and 3:1 
 
 
 
Increase of walking speed every 1-2 
weeks (individualized) 
Then increase of work-rest ratio, at 
fixed working time per session (10-
min) 
 
 
 
 
 
 
Lifelong, at least 2-3 times per week 
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Abbreviations: COR: Class of Recommendation; LOE: Level of Evidence; 6-MWT: Six-minute walk test 
 
The physiological bases of the program are as follows: 
i) When walking, patients with PAD must provide sufficient energy to satisfy the 
metabolic demand in the hypoxic area [409], and thus, aerobic support is crucial;  
ii) This condition can be evoked by a low to moderate degree of deoxygenation obtained 
with a low rather than high walking speed, to be progressively increased to create a 
continuous adaptive aerobic stimulus;   
iii) Extremely hypoxic conditions in the muscles may not be optimal to induce a 
favorable hemodynamic response. High-intensity fatiguing sessions (at moderate to 
near-maximal pain) that are typically prescribed in SET are associated with 
anaerobic rather than aerobic conditions [209,410] together with signs of muscular 
damage [410]; 
iv) A pain-free walking speed does not increase patients’ tolerance to pain, as in SET, 
but it may favor the patient’s adherence to exercise and an increase in spontaneous 
activity.  
It is known that exercise has the potential to stimulate vascular remodeling [411] and to lead 
to an increase in the number of mitochondria and in the level of oxidative enzymes [412-
413]. However, these adaptations are attainable through specific exercises carried out for 
sufficiently long periods at selected submaximal intensities [412,414-415]. Therefore, 
training should combine appropriate exercise intensity with an adequate duration. Sports 
physiologists recognize that at exercise intensities greater than the anaerobic threshold, the 
total volume of training is limited; conversely, training at the approximate intensity 
associated with the anaerobic threshold optimizes the intensity-duration relationship 
[408,416]. Thus, for the first time, an individual critical speed (PTS) determined during level 
walking, rather than a generic distance covered or time walked uphill, was proposed for 
assessment of the walking disability. This novel test [92,110] calls for small speed 
increments to synchronize the hemodynamic supply with the metabolic requirements of the 
patient, thereby preventing early activation of anaerobic glycolysis in the muscles involved 
in walking. Moreover, for the first time, a test was used to guide rehabilitation and to 
calibrate the exercise speed at home in PAD [408] as in sport sciences. Training just below 
the PTS might induce an “useful” degree of muscle hypoxia, associated with minimal or no 
pain, at an intensity that is sustainable for longer periods. This approach might favor the 
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induction of the well-known positive effects of aerobic training on vascular adaptations and 
on the cardiovascular system [123,209,412,415-416].  
Therefore, instead of walking at their individual speed or instead to prescribe continuous 
walking after pain onset [415], as for patients receiving a WA or treadmill-based SET [416], 
the program was based on walking sessions without pain, performed at home at low, 
progressively increasing speeds. Low-intensity exercise is carried out for short work units 
(ranging from 30 seconds to 5 minutes, generally 1-min per unit) to be repeated 3 to 10 times 
with periods of passive rest (1-2 minutes) after every single repetition. The combination of 
these factors, which contribute to the prescription in addition to the walking speed, is based 
on the individual degree of disability. The exercise prescribed at the hospital after a testing 
session is converted from walking speed into cadence or steps/min and precisely performed 
at home using a metronome. To test this hypothesis, in a small exploratory study, patients 
were free to choose one of three options: home-based walking guided by the pain threshold 
speed, walking at a self-selected speed through the pain, or no additional walking. After 120 
days, those patients walking around PTS obtained more evident significant functional and 
hemodynamic improvements than those who preferred to walk at the self-selected speed, 
with no changes observed in those who did not add an exercise to the usual habits [408]. 
In a nonrandomized controlled study [336] of a total of 143 patients with claudication, the 
effects of the Ti-To program on functional changes was compared with the WA or the 
traditional HB-free walking exercise. Ti-To was based on two daily 10-min home walking 
sessions at maximal asymptomatic speed with monthly check-ups at the hospital, while the 
traditional program was based on 20-30 min of daily walking at self-selected speeds up to 
pain tolerance (Figure 7).   
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Figure 7. Schematic description of the test in-train out (Ti-To) exercise program[337] 
 
After 6 months, the Ti-To group showed significantly greater improvements in walking 
ability as well as hemodynamic changes, which were completely absent in the group that 
performed the home-based free walking exercise [336].  
Confirmatory results to the physiological approach to exercise training in PAD proposed by 
Manfredini and colleagues were derived in the last 10 years using the NIRS. This technique 
noninvasively explores tissue microvascular hemodynamics, monitoring the local balance 
between oxygen delivery and its utilization [417] and allowing an objective study of muscle 
metabolism at rest and under dynamic and postexercise conditions [418-420]. NIRS, which 
revealed different patterns in early O2 desaturation or low muscle O2 extraction in low-
performing populations [421-423], has also been used to study PAD patients, whose 
performance depends on both oxygen availability and its use [424-427]. However, despite 
the potential usefulness, its routine use remains limited for PAD assessment [122]. Using this 
technique for several purposes, Manfredini and colleagues observed and reported the 
following results: 
- An altered pattern of deoxygenation in the calf muscle was determined during an 
incremental walking test at level walking on a treadmill in PAD patients [123]. This 
pattern can be useful for diagnosing PAD [123] in the presence of atypical symptoms 
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or in the presence of other conditions, e.g., diabetes, in which the ischemic pain is not 
reliably perceived and indicated by the patients [487], as well as in the presence of 
coexisting osteoarticular comorbidities, which are frequent in the elderly [339]. 
Moreover, early deoxygenation in the muscles of PAD patients at a low walking speed 
(often approximately 1.5 km/h) has been observed, providing valuable information 
about the exercise prescription [123]. This finding confirms the rationale based on 
walking from low to progressively higher speed to induce aerobic adaptations. 
- Studied hemodynamic adaptations following different types of exercise programs 
with NIRS were revealed only in the group performing the low intensity pain-free 
interval Ti-To program and not in those walking at higher speed through the pain 
[340], confirming the starting hypothesis.   
Hemodynamic adaptations were also studied following surgery in comparison to 
walking training (unpublished) in a randomized trial [168], confirming the presence 
of a hemodynamic response to the Ti-To program that was even markedly lower than 
in the revascularization group. 
- Biomarkers of deconditioning in PAD patients, especially in more severe patients, 
have been observed using the NIRS technique, such as an abnormally high value of 
muscle oxygen consumption at rest [124]. This “altered” biomarker has also been 
observed in patients with multiple sclerosis and ESRD, when it was reversed 
following Ti-To training [429-430]. 
- A selective degree of perfusion of the foot in ischemic patients with possible altered 
microcirculation was determined using a toe-flexion NIRS-based test [126]. This test 
also allowed the determination of possible hemodynamic tolerability and safety 
concerning the use of elastic compression in patients with PAD and concomitant 
chronic venous insufficiency [126-127]. 
The organizational aspect is another important issue of the Ti-To SH-BEx program. In 
addition to a general improvement of hemodynamic, functional and QoL parameters [337], 
the organizational model was found able to favor adherence [337-339], overcoming barriers 
to exercise. The patient has the possibility to comfortably carry out all the exercises at home, 
safely and sometimes together with the spouse, who controls the exercise execution (and 
sometimes also starts the program). The daily low dose of exercise can also be performed by 
poorly performing patients with comorbidities. Moreover, requiring an acceptable and fixed 
working time, the exercise is easily inserted into daily life. The program calls for few visits 
to the hospital, with low costs and a negligible or sustainable commitment on the part of the 
Terapia de ejercicios para enfermedades crónicas: Discapacidad y resultados clínicos a largo plazo en una cohorte de 
pacientes con enfermedad arterial periférica inscritos en un programa de rehabilitación original 
 
 100 
family [337], while a supervised program requires the need to travel daily or three times a 
week to facilities for exercise execution [431]. One such original approach is based a 
rehabilitative program that is actually available for PAD patients at the University Hospital 
of Ferrara, carried out in an outpatients setting. A rehabilitative team, including a medical 
doctor, a nurse and an expert in sport sciences, follows the rehabilitation of 200 patients/year. 
The program, which does not require specific or expensive instruments and is therefore 
reproducible in any setting [337,432], is offered to patients without cost, which is possible 
because of the low organizational costs. A study [337] developed in cooperation with the 
Department of Economy of the University of Ferrara on 250 consecutive patients showed a 
favorable cost-effectiveness ratio (9 Euros/walking meter gained), which was significantly 
lower than previously reported costs ranging from 27 to 57.5 Euros or 4,179 Euros for a 
whole program [433-437]. For both physiological and organizational reasons, the model was 
successfully implemented in patients with chronic diseases other than PAD. The Ti-To 
program has been tested in stroke survivors at home and in a community-based version [438-
439]. In particular, the model was adapted to dialysis patients, for whom, in a pilot study, it 
showed an improved quality of life and functional parameters [440], as well as increased 
mobilization of EPCs [341]. Interestingly, these cells, the baseline level of which is related 
to the degree of exercise capacity [242], show an increase that is directly and significantly 
correlated to the patient-reported training load [341]. The program was successfully tested in 
a national multicenter trial, EXCITE (EXercise InTroduction to Enhance performance in 
Dialysis [441]), which represents the largest study of home-based exercise in ESRD. The 
semipersonalized low-intensity exercise program showed a significant improvement of 
performance as well as a favorable impact on QoL and rate of hospitalizations [442-443], 
with favorable effects up to 36 months of follow-up. The program among dialysis patients 
was safe, with no danger reported by patients during 11,325 certified walking sessions and 
suitable for elderly patients [444]. Analysis of this trial data using multivariate Cox models 
showed that an increase in mobility (20-meter walked during the 6MWT) was associated 
with a 6% reduction of risk for the composite endpoint of mortality, cardiovascular events 
and hospitalizations, and a similar relationship was observed among the 6MWT, mortality 
and hospitalizations [442,444]. Finally, the program was successfully performed under 
supervision in severe multiple sclerosis patients with blood flow restriction, with improved 
gait speed [445]. 
The differences in terms of training features and rehabilitation outcomes, in the different 
studies reporting various models of exercise training, are summarized in Table 11.  
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Table 11. Characteristics and effects of different models of exercise-based interventions in peripheral artery disease proposed by different authors. 
  
 
  
Model Source/ Guidelines Session location sessions/week Intensity INTERVALS PAIN Prescription recording duration visits Objective (s) functional changes Hemodynamics
 intervention author COR/Loe duration walking speed months   (ABI)
inside time and speed increased 
SUPERVISED TASC I A 30-60 minutes hospital 3 treadmill pain-limited near maximal according to symptoms not necessary 3 12 exercise capacity significant no change
[ref #3] including rest periods 3  4 out of 5 patient and operator based claudication time superior to unsupervised
HOME BASED McDermott MM IIa  A time and speed increased distance walked
STRUCTURED [ref #448] 10-50 minutes/session. outside ?? self-selected pace pain-limited severe leg discomfort according to symptoms fit bit 9 4 6MWT no vs control no change
USA randomized 12-14/20 Borg patient-based web immission
HOME BASED Gardner AW IIa  A   pain-limited mild-to moderate time and speed increased exercise capacity
STRUCTURED [ref #99] 20–45 minutes/session outside 3 self-selected pace based claudication pain according to symptoms step monitor 3 4 claudication time significant no change
USA randomized patient-based exercise logs
HOME BASED Manfredini F IIa  A 20 minutes structured increase of speed ABI changes
STRUCTURED [ref #337] (40 min including rest) inside 5    6 slow to moderate pace time-based pain-free and work rest ratio exercise logs 6 4−6 exercise capacity significant significant
FERRARA controlled alternative divided in two daily sessions home progressively up 0-1/10 operator-based sustainable walking speed superior to unsupervised superior to unsupervised
non randomized to  self-selected indivualization (perodic tests) hemodynamics
HOME BASED literature 0 20-30 minutes outside 3  5 self-selected pace pain-limited 3-4  di 5 generic no ? ? distance walked no change
UNSTRUCTURED
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Early identification of the PAD patient and start of the appropriate combined therapy may 
prevent progression of the disease, amputation and MACE, as well reduce walking disability 
and functional decline.  
Evidence supports the effectiveness of exercise in PAD, in particular of the SET programs, 
also considering the limited availability of medical therapies available to improve their 
walking performance [52]. However, structured community- or home-based programs for 
patients with PAD are gaining consideration [97,99,352,354,368,446] for their characteristics 
as well also for the attainment of greater improvements in ground walking compared with 
supervised exercise interventions [96-99,368].   
Evidence suggests that exercise programs also significantly improve walking endurance in 
asymptomatic patients with PAD who are at risk of mobility loss [77,106,191,203-204,310].  
In addition to the evidence, gray areas are still present in the available literature, and some 
problematic issues have recently been discussed by the AHA with the creation of a “to-do 
list” that includes the research priorities [77]. 
SET shows less benefit for patients who are very limited in their walking ability [77], with a 
negative response to ischemia-inducing exercise training and decrease in mitochondrial 
function in patients with greater disease severity [77]. Previous observations have reported 
an association between repeated episodes of ischemia with negative effects on the limb 
musculature with altered skeletal muscle structural and metabolic properties [230-231,233]. 
Alternative exercise strategies for PAD patients should be considered [77], especially for 
more affected or limited patients, and the variability in responses and nonresponses to 
different exercise therapies should be evaluated [77]. The fundamentals of the SET and of 
exercise modalities (intensity, duration, frequency, work-to-rest ratios, etc.) should be studied 
in greater detail, and alternative forms of exercise walking, which differ from SET and in 
general from exercise to moderate-severe IC pain, should be considered. Less intense training 
was found to be effective [410], and a lower degree of increased ischemia-induced 
inflammation improved mitochondrial function with a positive response to an exercise 
program [179]. A study published very recently [447] has shown that oxygen-guided exercise 
training assisted by NIRS improves claudication comparable to pain-based training regimens, 
with adaptations in mitochondrial function accounting for the functional improvement. The 
oxygen-guided training intensity was determined by maintaining a 15% reduction in skeletal 
muscle oxygenation by NIRS rather than relying on symptoms of pain to determine the 
exercise effort [447]. This level corresponds to training below the pain threshold speed 
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proposed in 2004 by Manfredini et al. and is related to the rationale of the Ti-To program as 
well as the physiology of aerobic adaptations [408].  
Again, according to the recent AHA statement [77], “further identification of biological 
mechanisms that underlie improvement in response to exercise training has the potential to 
advance the field”. Ultimately, in vascular disease, the issue of vascular adaptations cannot 
remain unconsidered. It is generally accepted, and recently confirmed, that a minimal, with 
moderate to no increase, ankle–brachial index or calf blood flow in humans is associated with 
SET exercise [87,169,181]. Interestingly, training models at submaximal intensity that avoid 
ischemia-induced inflammation, such as the Ti-To program, are associated with 
hemodynamic improvements [168,336-340]. In general, programs that are not only 
considered to lead to an improvement of walking efficiency and pain tolerance but that 
attempt to fully exploit the potentialities of aerobic exercise may be of interest to patients with 
more severe disease and/or disability. The present study aims to support this concept.  
In addition, as stated in the recent AHA scientific document [77], “Strategies to translate SET 
for patients with PAD from the research laboratory to the clinical setting are greatly needed”. 
Trials may exclude patients who represent a population of present and future interest due to 
the aging of the population, and therefore, different type of studies should be of potential 
interest (e.g., pragmatic trials), in addition to different primary outcomes (hemodynamics, 
QoL, etc.) or sex-specific outcomes. In addition, studies designed to increase the participation 
of patients with PAD in exercise therapy and to favor the transition of patients from 
supervised, hospital-based settings to community-based settings are necessary to result in a 
change in lifestyle [77]. 
However, the candidate and group of collaborators who have succeeded since the late 1990s 
have been considering most of these doubts and have attempted to identify, test and make 
clinically feasible new training strategies. This approach has allowed the definition of a 
sustainable model of intervention, especially in frail and more disabled patients.  
Waiting for funding to support a trial, the present study aims to retrospectively analyze the 
results obtained in a large population following a Ti-To program. Interestingly, one of the 
research priorities of the AHA is solely the evaluation of long-term functional and 
cardiovascular risk outcomes of participation in exercise programs [77]. The present study 
aims to understand whether the proposed patient-based intervention may be effective not only 
at discharge but also over the long-term in relation to the adaptations that occur during the 
program. 
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In particular, the primary outcome of the three-year revascularization risk in the elderly with 
moderate and severe disease is a new piece of information in the literature of possible 
growing interest.  
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HYPOTHESIS 
 
The functional and hemodynamic adaptations evoked by a structured aerobic intervention 
would favor long-term vascular outcomes, even in severe PAD.  
 
OBJECTIVES 
 
General objective 
 
To determine whether a rehabilitation program altered the rate of PAD-related 
revascularization and mortality three years post-discharge in a cohort of elderly patient. 
 
Specific objectives 
 
- To know the hemodynamic and functional changes following a rehabilitation 
program in a population of elderly PAD patients. 
- To evaluate the risk of PAD-related revascularization at a three-year follow-up. 
-     
- To establish the relationship between the outcomes of the rehabilitation program and 
the risk of PAD-related revascularizations. 
-   
- To establish the relationship between the outcomes of the rehabilitation program and 
the risk of all-cause mortality.  
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1. DESIGN, POPULATION, SETTING, PERIOD AND ETHICAL 
CONSIDERATION 
 
This single-center study retrospectively analyzed a prospectively collected database of PAD 
patients who were referred to the vascular rehabilitation program at the University Hospital 
of Ferrara between 2005 and 2013. In the prospective approach, 835 consecutive patients 
with PAD at Fontaine’s stage II who were previously diagnosed at the Department of 
Vascular Surgery were enrolled in the study.  
The local ethics committee approved the study and written informed consent was not 
obtained from patients who were no longer attending the program.  
 
2. STUDY VARIABLES, INCLUSION AND EXCLUSION CRITERIA 
 
The ABI was measured at the beginning of, during, and at discharge from the program 
according to the established standards [25]. An incremental treadmill test based on level 
walking [92] was performed to determine the speed at onset of symptoms and the maximal 
speed (Smax) attainable for each patient.  
The patients who did not complete the rehabilitation program, had an ABI >0.8 at baseline 
or was non-measurable, were aged <60 or >80 years, or had missing/incomplete information 
regarding long-term outcomes, were excluded. 
To perform all the analyses, the final PAD population was divided into two groups according 
to disease severity at entry: severe (Sev), for ABI values ≤0.5 in the more impaired limb and 
moderate (Mod) for ABI values >0.5.  
The improvement obtained at the end of the program compared to the baseline was 
categorized according to previous prospective studies for further analyses [168,336,340]. The 
following favorable outcomes were considered: for hemodynamics, an ABI value increase 
≥0.10 for the more impaired limb; and for functional capacity, Smax variations ≥0.5 km/h.  
 
3. EXERCISE PROGRAM AND INSTRUMENTS 
 
All patients received the “test in–train out” home-based exercise program [336,337]. The 
structured exercise was prescribed at the hospital during circa-monthly visits, but it was 
executed at home. The program encompassed two daily 10-minute sessions of intermittent 
walking (one-minute walk followed by one-minute seated rest) for six days each week at a 
Terapia de ejercicios para enfermedades crónicas: Discapacidad y resultados clínicos a largo plazo en una cohorte de 
pacientes con enfermedad arterial periférica inscritos en un programa de rehabilitación original 
 
 116 
prescribed speed. The training speed was converted into a walking cadence (steps/minute) 
and paced at home by using a metronome. It was slower than the individual’s walking speed 
at the beginning and increased weekly. A record of the training sessions was requested and 
collected at each visit. The patients were discharged from the program when a satisfactory 
and/or stable improvement in pain-free walking distance was attained. More details on the 
exercise program are reported elsewhere [336,337]. 
 
4. OUTCOMES  
 
PAD-related lower limb revascularization was the primary outcome and all-cause mortality 
was another outcome of interest. Outcomes were considered after the date of participants’ 
discharge from the program. The clinical data for a 3-year follow-up period after the 
discharge date were gathered from the Emilia-Romagna health service registry.  
 
5. STATISTICAL ANALYSIS 
 
Differences in baseline characteristics were assessed according to PAD severity. Differences 
were assessed using chi-squared tests, Student’s t-test, or the Mann-Whitney U-test as 
appropriate. Logistic regression with a stepwise selection method was used to identify the 
factors related to a non-response to rehabilitation.  
Kaplan-Meier estimates of the distribution of times from discharge to the clinical events and 
a log-rank test for trend were used to compare the curves of the four patient subgroups (Sev 
and Mod, with/without hemodynamic or functional improvement). Data for peripheral 
revascularization were censored at the time of death. 
Univariate and multivariate Cox proportional hazards regression analyses were used to 
analyze the effect of several predictor variables on the primary outcome in the entire 
population and in each of the two groups. Because of the limited number of events, 
multivariate hazard ratios (HRs) were calculated using a forward approach, with an entry 
limit of p < 0.05.  
A p value of <0.05 was considered statistically significant. All statistical analyses were 
performed using MedCalc Statistical Software version 18.10 (MedCalc Software bvba, 
Ostend, Belgium). Research data are available at: http://dx.doi.org/10.17632/4536z7c3nk.1. 
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From January 2005 to January 2013, 835 patients with PAD were enrolled in the 
rehabilitation program. A flow diagram of the participants and the reasons for exclusion are 
reported in Figure 8.    
Figure 8. Flow diagrams of participants. 
 
Abbreviations: PAD: Peripheral Artery Disease; ABI: Ankle-Brachial index; n: number 
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The final sample for this study included 457 elderly patients; 146 patients were severe (Sev) 
and 311 patients were moderate (Mod). The baseline demographics and clinical 
characteristics of the two subgroups, which differed by more prevalent bilateral disease in 
Sev, both limbs’ ABI and functional capacity, are shown in Table 12. 
Table 12. Baseline characteristics of patients included in the analysis. 
 Moderate  
(n = 311)  
Severe  
(n = 146)  
p 
Male sex 223 (72) 110 (75) 0.41 
Age, years 71 ± 6 72 ± 5 0.07 
Sedentary occupation 209 (67) 89 (61) 0.19 
Risk factors; n (%)    
Smoking 277 (89) 134 (92) 0.37 
Hypertension 247 (79) 121 (83) 0.38 
Hyperlipidemia 218 (70) 103 (71) 0.92 
Diabetes mellitus 119 (38) 54 (37) 0.79 
Chronic Kidney Disease 30 (10) 20 (14) 0.20 
Familiarity for CVD 72 (23) 35 (24) 0.85 
Comorbidities; n (%)    
Chronic Heart Disease 123 (40) 63 (43) 0.47 
Stroke 35 (11) 16 (11) 0.93 
Osteoarticular disease 78 (25) 35 (24) 0.80 
Pulmonary disease 18 (6) 15 (10) 0.08 
Neoplastic disease 25 (8) 14 (10) 0.58 
Charlson Comorbidity Index  2.6 ± 1.4 2.7 ± 1.5 0.51 
Age-adjusted Charlson Index 6.2 ± 1.5 6.4 ± 1.6 0.27 
Peripheral artery disease    
Grade I—Category 1 168 (54) 31 (21) <0.001 
Grade I—Category 2 118 (38) 55 (38) <0.001 
Grade I—Category 3 25 (8) 60 (41) <0.001 
Self-reported claudication distance (m) 209 ± 187 114 ± 121 <0.001 
Lower limbs revascularization 85 (27) 49 (34) 0.17 
Disease duration, years 6 ± 6 7 ± 6 0.09 
Bilateral disease 206 (66) 119 (82) <0.001 
ABI more impaired limb 0.64 ± 0.08 0.39 ± 0.10 <0.001 
ABI less impaired limb 0.86 ± 0.16 0.66 ± 0.22 <0.001 
PTS (km/h) 2.9 ± 1.1 2.5 ± 0.9 <.001 
Smax (km/h) 3.4 ± 1.1 3.0 ± 1.0 < 0.001 
Abbreviations: CVD: cardiovascular disease; ABI: ankle-brachial index; PTS: speed at symptoms; Smax: 
maximal speed. Legend: Disease severity is reported according to Rutherford classification[22]. 
 
1. EXERCISE PROGRAM 
 
All patients completed the exercise program, which lasted 394 ± 177 days, but the number 
of days was significantly greater in the Sev group than the Mod group (433 ± 188 vs. 376 ± 
169 days, respectively; p = 0.001). Adherence to the program at a controlled speed was high 
for both groups, with both executing 87% of walking sessions prescribed (p = 0.77).  
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Significant improvements in the ABI of both limbs and Smax were observed at the end of the 
program in the entire population and both groups. Significant between-group differences 
were found for both ABI values in favor of the Sev group (<0.001). (Table 13, Figure 9). 
Table 13. Within- and between-group differences in rehabilitation outcomes. 
 
Abbreviations: ABI: ankle-brachial index; PTS: speed at symptoms; Smax: maximal speed.  
Legend: Data are expressed as mean and 95% Confidence Interval.  
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Figure 9. More impaired limb Ankle-Brachial Indexes (upper) and maximal speed (lower) 
distribution in the whole population at baseline (blue) and at discharge (orange) 
 
 
For long-term outcome analyses, 71 Sev patients (49%) improved to ABI ≥ 0.10 (SevABI+) 
and 75 (51%) achieved enhanced Smax ≥0.5 km/h (SevSmax+). Eighty-eight (28%) of the Mod 
patients had improved ABI (ModABI+) and 164 (53%) achieved enhanced Smax (ModSmax+).  
The regression models for the entire population and both groups, including the independent 
variables related to subjects, risk factors, comorbidities, and PAD characteristics (Table 1), 
did not identify any factors related to a non-response to rehabilitation when ABI and Smax 
improvements were considered.  
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2. PRIMARY OUTCOME: PAD-RELATED REVASCULARIZATION 
 
Fifty-six (12%) patients in the whole population had undergone peripheral revascularization 
at the 3-year follow-up; 25 from the Sev group (17%) and 31 from the Mod group (10%) 
(log-rank p = 0.006). 
Considering the rehabilitative outcomes, analyses of the ABI change showed a 3-year 
revascularization rate of 21% in SevABI−, 13% in SevABI+, 11% in ModABI− and 7% in ModABI+ 
(Figure 10A). Similar rates were observed for functional capacity improvements, particularly 
21% in SevSmax−, 13% in SevSmax+, and 10% in both Mod subgroups (Figure 10B).  
For both analyses within the Sev subgroups, the hemodynamic or functional improvement 
resulted in a protective, although not statistically significant, HR of 0.52 (0.20–1.40) and of 
0.55 (0.20–1.50), respectively, which was enhanced in the case of concomitant improvements 
of the two outcomes (HR 0.43; 0.13–1.36) (Figure 10C).  
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Figure 10. Kaplan-Meier curves of revascularizations in the four patients’ subgroups according to 
disease severity and ABI (A), or maximal speed improvements (B), or both (C). 
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3. SECONDARY OUTCOME 
 
There were 69 deaths (15%) during the study period; 43 in the Sev and 26 in the Mod group 
(29% vs. 8%, respectively, log-rank p < 0.001). Higher mortality rates were observed for 
SevABI− (31%) compared to the other subgroups, including SevABI+ (28%), ModABI− (9%), 
and ModABI+ (6%) (Figure 11A). Similarly, the subgroup SevSmax- showed a higher mortality 
at 37% compared to SevSmax+ (23%), ModSmax− (8%), and ModSmax+ (9%) (Figure 11B). No 
statistically significant differences were observed between the Sev subgroups. 
Figure 11. Kaplan-Meier curves of survival in the four patients’ subgroups according to disease 
severity and ABI (A), or maximal speed improvements (B).  
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4. PREDICTORS OF REVASCULARIZATION 
 
History of myocardial infarction (HR: 1.90; 1.07–3.36) and the ABI value of the more 
impaired limb at discharge (HR: 0.03; 0.004–0.16) were the only predictors of peripheral 
revascularizations in the entire population according to multivariate Cox regression. The 
univariate analyses highlighted the impact of baseline ABI values and their changes 
following rehabilitation (Figure 12, Table 14). 
Figure 12. Forest plot showing association between PAD-related revascularizations and study 
variables in the whole population. 
 
Abbreviations: ABI: Ankle-braquial index; Smax: maximal speed 
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Table 14. Results of Cox proportional hazards regression analyzing the capability of the study 
variables for the prediction of 3-year revascularization in the whole population and in the two patient 
groups. 
 
Abbreviations: HR: Hazard Ratio; ABI: Ankle-brachial index; Smax: maximal speed 
 
 
Several independent predictors were identified in the Sev group, but the ABI improvement 
in the more impaired limb was the most protective factor against peripheral revascularization 
(HR: 0.003; 0.0001–0.09), which reduced the risk by greater than 300%.  
Only chronic kidney disease and the ABI of the more impaired limb at discharge were 
included in the analysis in the Mod group (Table 14, Figure 13).  
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Figure 13. Forest plots showing association between PAD-related revascularizations and study 
variables in the Moderate (A) and Severe (B) groups. 
 
Abbreviations: ABI: Ankle-brachial index; Smax: maximal speed  
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This retrospective study shows for the first time that hemodynamic and functional changes 
following a rehabilitation program in a population of elderly PAD patients are associated 
with a significant reduction in the risk of PAD-related revascularization at a three-year 
follow-up. Notably, the severe PAD patients who attained some degree of hemodynamic and 
functional changes showed a lower risk of limb revascularizations that was comparable to 
patients with moderate disease. As a starting point, the present study confirmed the 
effectiveness of a structured, home-based program [168,336,337] on exercise capacity in the 
entire population and both PAD subgroups. Patients with severe disease and significantly 
lower functional values at baseline achieved the same improvements as patients with 
moderate disease. A significant ABI increase was also observed in the entire population and 
both PAD subgroups, which has been observed in previous studies [168,326,336-
337,340,449] and poorly reported following supervised programs [169]. Notably, 
hemodynamic changes were more evident in the severe PAD patients. However, the most 
significant aspect of the study reveals an important, yet poorly reported, effect of 
rehabilitation on long-term outcomes and particularly the vascular interventions in PAD. 
The clinical outcomes of the entire PAD population under study after three years were 
comparable or even better than previous reports in the literature [76,450-451]. A rate of 12% 
of vascular intervention (2.6% for acute limb ischemia) was observed, with 0.8% amputations 
and 15% deaths. As expected and previously reported [185,187-188], worse vascular and 
clinical outcomes at three years were observed in PAD patients with severe disease, with a 
2−3-fold higher rate of events compared to patients with moderate disease (17% vs. 10% for 
interventions and 8% vs. 29% of deaths, respectively). 
Previous studies reported negative outcomes (deaths, functional decline, re-interventions) 
associated with low exercise capacity [76,100], negative changes of ABI over time [186,190], 
and rehabilitation poorly attended [452] or not combined to revascularization [453]. 
Notably, the present study showed that it was not the functional and hemodynamic values at 
baseline, but the variations in these factors following rehabilitation that were primarily 
associated with the fate of elderly patients. Namely, the improvements observed at discharge 
from the program reduced the relative risk of lower limb revascularizations at a three-year 
follow-up, especially in the population with severe disease. The ABI improvement of the 
more impaired limb in this group of patients represented the most protective factor against 
peripheral revascularization, with a reduction in risk of over 300%. In particular, an ABI 
improvement ≥0.10 was a relevant outcome that was associated with a lower risk of future 
interventions. This hemodynamic change, associated with personalized aerobic training, may 
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have favored a significant gain in mobility in a subgroup of severe patients. Those who 
attained hemodynamic and functional improvements showed vascular outcomes that were 
almost comparable to the moderate group and a lower mortality rate. The data collected 
highlight the role of rehabilitation, considering that interventional procedures may be not 
effective or satisfactory for mobility [453-454] in patients with intermittent claudication. 
The present study demonstrated the sustainability of the program, which bypasses most 
barriers of the supervised programs [431,455]. The program is without gender differences 
[338] or limitations from pre-existing osteoarticular pathologies [339] and enables the 
enrolment of frail patients with restricted mobility. This exercise is based on over-ground 
personalized walking sessions inside the home and it is safe and painless [337]. The duration 
of the program, which was deliberately made longer in the severe group, allows for a 
protective monitoring of lifestyle and therapy adherence [456]. The program calls for few 
hospital visits, which maintains a low cost for the National Health Service [168,337].  
This study has several limitations. First, its retrospective design may have influenced data 
recording. However, the same team prospectively collected the data from patients enrolled 
consecutively, and the data were secondarily elaborated and analyzed by personnel who were 
not involved in the study. A control group not exposed to rehabilitation is absent, but the 
objective was to explore the long-term response to the measured hemodynamic and 
functional effects of rehabilitation. The cut-off values for the analyses of the rehabilitative 
outcomes were arbitrary but in accordance with previous studies [168,337,340]. Patients with 
non-measurable ABI were excluded because it was not possible to classify them according 
to hemodynamic severity. Patients aged over 80 years were also excluded on the basis of the 
life expectancy in our province (average of 82.2 years). 
Finally, a treadmill test was used instead of an over-ground walking test to favor 
standardization. 
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A structured home-based rehabilitation program evoking functional and 
hemodynamic improvements reduced the long-term risk of vascular outcomes and deaths in 
elderly patients with claudication and in the presence of severe PAD.  
The hemodynamic and functional changes are associated with a significant reduction 
in the risk of PAD in a population that follow a rehabilitation program. 
Patients with severe disease and significantly lower functional values at baseline 
achieved the same improvements as patients with moderate disease  
The rehabilitation program shows effectiveness on long-term outcomes and 
particularly on the vascular interventions in PAD patients. 
A lower risk of mortality was also associated to the hemodynamic and functional 
improvements at the end of rehabilitation.  
As implications of clinical practice, patient-centered programs may represent an 
option in the decision-making for elderly patients with low mobility and severe disease, but 
a prospective study is warranted to confirm the data presented in this study. 
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